Large-scale combinatorial CAR transduction and CRISPR gene editing of MSC cells

By performing CAR transduction and CRISPR gene editing on MSCs, their survival and durability are enhanced, which solves the problem of limited efficacy of existing cell immunotherapy against malignant tumors and achieves more effective cancer treatment.

CN114945377BActive Publication Date: 2024-11-12BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080092838.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-27
Filing Date
2020-11-25
Publication Date
2024-11-12
Estimated Expiration
2040-11-25

AI Technical Summary

Technical Problem

Existing cell immunotherapy methods have limited effectiveness against most malignant tumors, especially solid tumors. This is mainly due to reduced expression of tumor antigens on the surface of tumor cells, expression of inhibitory receptors, upregulation of cell checkpoints, and the presence of inhibitory cells in the microenvironment, which lead to suppressed immune responses and tumor cell proliferation.

Method used

By performing CAR transduction and CRISPR gene editing on mesenchymal stem cells (MSCs), their viability and durability can be enhanced, apoptosis can be reduced, cells can be modified to express heterologous antigen receptors and endogenous repressive genes can be destroyed, thereby improving their efficacy in cancer treatment.

Benefits of technology

It enhances the anti-cancer activity and persistence of MSCs, improves the therapeutic effect on cancer, and prolongs the survival of cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114945377B_ABST
    Figure CN114945377B_ABST
Patent Text Reader

Abstract

Embodiments of the present disclosure encompass methods and compositions for producing engineered mesenchymal stem cells / mesenchymal stromal cells (MSCs). The present disclosure relates to a large-scale method for producing MSCs that can be engineered using CRISPR to disrupt the expression of one or more genes and also express at least one heterologous antigen receptor. Specific embodiments include specific parameters for the method.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 941,663, filed on November 27, 2019, which is incorporated herein by reference. Technical Field

[0002] The present disclosure relates generally to at least the fields of immunology, cell biology, molecular biology, and medicine. Background Art

[0003] Cellular immunotherapy holds great promise for the treatment of cancer. However, most immunotherapy approaches have limited value for most malignancies (especially solid tumors) when applied alone. Reasons for this limited success include (1) reduced expression of tumor antigens on the surface of tumor cells, which reduces their detection by the immune system; (2) expression of ligands for inhibitory receptors, such as PD1, NKG2A, and TIGIT; (3) upregulation of cellular checkpoints, such as CISH, which induces inactivation of immune cells; and (4) induction of cells in the microenvironment (such as regulatory T cells or myeloid-derived suppressor cells), which release substances that suppress immune responses and promote tumor cell proliferation and survival, such as transforming growth factor-β (TGFβ) and adenosine. Therefore, there is an unmet need for improved cellular immunotherapy approaches, including methods to address these aspects. Summary of the invention

[0004] Embodiments of the present disclosure include methods and compositions for enhancing the activity of mesenchymal stem cells / mesenchymal stromal cells (MSC) when used for adoptive cell therapy applications. In specific embodiments, the present disclosure relates to enhancing the viability and persistence of MSCs, which are specially engineered to have enhanced viability and persistence compared to corresponding MSC cells that are not so engineered. Specific embodiments include methods and compositions for reducing apoptosis of MSCs, which are specially engineered to reduce the risk of apoptosis compared to MSCs lacking the same or similar engineering. The disclosed methods utilize specific parameters to improve the expansion of MSCs and improve their efficacy for use as a therapy for individuals in need.

[0005] Specific embodiments of the present disclosure include novel large-scale methods (including GMP grade) for combined CAR transduction and CRISPR gene editing for MSC (e.g., including from bone marrow, umbilical cord tissue, peripheral blood, adipose tissue, dental pulp or a mixture thereof). The present disclosure provides an engineered MSC that expresses one or more heterologous antigen receptors and has been gene-edited to destroy one or more endogenous genes in MSC. In some embodiments, the MSC transduced by CAR is engineered to destroy the expression of one or more endogenous genes in MSC cells, and in other embodiments, the MSC cells with the destruction of the expression of one or more endogenous genes in MSC cells are transduced or transfected to express one or more heterologous antigen receptors. Specific embodiments provide gene editing (including large-scale CRISPR / Cas9-mediated) engineering strategies for primary MSC (including MSC transduced by CAR).

[0006] In certain embodiments, the methods utilize a method that allows the method to be scaled up (including engineering up to 1×10 9 The disclosure allows modification of cells to have one or more heterologous antigen receptors and the expression of one or more endogenous genes lacking MSC or the expression of one or more endogenous genes with reduced MSC. In certain cases, CRISPR and guide RNA are used to knock out or knock down one or more endogenous genes, including multiple genes (when necessary). In certain embodiments, in addition to knocking out or knocking down endogenous genes and in addition to expressing heterologous antigen receptors, MSC is modified in one or more ways. In some cases, the method also includes a specific duration for a specific step of the method.

[0007] The MSC produced can be used for any purpose, including for the treatment of medical conditions, such as cancer, infectious diseases and / or immune-related disorders. In some embodiments, MSC is appropriately stored before use. In terms of cell source, the recipient individual of engineered MSC can be autologous or allogeneic. In some cases, after appropriate storage, the MSC produced by the method of the present disclosure is used for therapeutic purposes, and may or may not be further modified after storage and generation. For example, MSC can be engineered to perform gene editing on one or more endogenous genes in the cell to promote their viability, and then store MSC, but before use, MSC can be further modified to express one or more heterologous antigen receptors, which are specific to the needs of the recipient individual, such as receptors targeting antigens on individual cancer cells. In other cases, MSC can be modified to express one or more heterologous antigen receptors, including, for example, antigens of known cancer antigens, and then store MSC, but before use, MSC can be further modified to perform gene editing to destroy the expression of one or more endogenous genes. In this example, heterologous antigen receptors can be designed or not designed to target well-known cancer antigens, or antigens present on a variety of cancer cell types.

[0008] In a specific case of the method, the CRISPR step is further defined as comprising two or more delivery steps. In this case, the first delivery step may include delivering a guide RNA targeting one or more genes, and the second delivery step may include delivering a guide RNA targeting one or more genes, the genes in the second delivery step being different from the one or more genes in the first delivery step. In a specific example, the duration between the first delivery step and the second delivery step is at least about two days, or the duration between the first delivery step and the second delivery step is about two to three days. In a specific embodiment, one or more CRISPR-related compositions are delivered to MSCs by electroporation. In the case where cells are electroporated, electroporation can use a specific amount of cells, such as about 200,000 cells to 1x10 9 MSCs. About 200,000 to 2,000,000 cells can be used for electroporation. About 1,000,000 to 1x10 9 MSCs.

[0009] In certain embodiments, the heterologous antigen receptor is one or more chimeric antigen receptors and / or one or more T cell receptors and / or one or more death receptors (TRAIL, FAS ligand).The heterologous antigen receptor may target cancer antigens, including tumor-associated antigens. In certain instances, the heterologous antigen receptor targets an antigen selected from the group consisting of CD19, CD319 (CS1), ROR1, CD20, carcinoembryonic antigen, alpha-fetoprotein, CA-125, MUC-1, epithelial tumor antigen, melanoma-associated antigen, mutated p53, mutated ras, HER2 / Neu, ERBB2, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, GD2, CD5, CD123, CD23, CD30, CD56, c-Met, mesothelin, GD3, HERV-K, IL-11Rα, kappa chain, lambda chain, CSPG4, ERBB2, WT-1, TRAIL / DR4, VEGFR2, CD33, CD47, CLL-1, U5snRNP200, CD200, BAFF-R, BCMA, CD99, and combinations thereof.

[0010] In a particular embodiment, the gene having a disruption in expression in the MSC is any one or more genes whose disruption renders the MSC more suitable for treatment than in the absence of such disruption. In a specific embodiment, the gene is an inhibitory gene, such as an inhibitory gene selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, TDAG8, CD5, CD7, SLAMF7, CD38, LAG3, TCR, β2-microglobulin, HLA, CD73, CD39, and combinations thereof.

[0011] In some embodiments, MSCs are engineered to express one or more heterologous cytokine genes, such as IL-2, IL4, IL10, IL-12, IL-15, IL21, IL22, TNF-α, interferon α, interferon β, etc.).

[0012] In any method herein, any cell produced by functional assay, cytotoxicity assay and / or in vivo activity analysis, including cells analyzing the degree of gene disruption. In a specific embodiment, the cell is analyzed by flow cytometry, mass spectrometry flow cytometry, RNA sequencing, PCR or a combination thereof. According to the method, any cell can be stored, for example, cryopreserved. Any cell of an effective amount can be delivered to an individual in need, for example, an individual suffering from cancer, infectious disease and / or immune-related disorder.

[0013] Embodiments of the present disclosure include MSC cell populations produced by any of the methods contemplated herein. Compositions comprising a cell population of the present disclosure are contemplated, including when the population is in a pharmaceutically acceptable carrier.

[0014] Embodiments of the present disclosure include methods of treating a medical condition in an individual, comprising the step of administering to the individual a therapeutically effective amount of MSCs produced by any of the methods of the present disclosure. The MSCs may be administered to the individual one or more times. The individual may or may not have received, is receiving, or will receive one or more additional therapies for the medical condition.

[0015] Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, although indicating specific embodiments of the present disclosure, are given by way of illustration only, because various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art based on the detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] For a more complete understanding of the present disclosure, reference is now made to the following description taken in conjunction with the accompanying drawings.

[0018] Figure 1 . Schematic diagram of examples of CAR transduction and CRISPR Cas9 editing protocols for human mesenchymal stromal (MSC) cells from different sources.

[0019] Figures 2A-2D .MSC transduction efficiency. Figure 2A ) Representative histograms show that bone marrow (BM)-derived MSCs (left) and umbilical cord tissue (CT)-derived MSCs (right) were transduced with a retroviral vector expressing CAR CD5, with an efficiency of 66.5% for BM MSCs (blue) and 98.4% for CT MSCs (blue; rightmost peak) compared to untransduced MSCs (red; left-most peak) and isotype (grey; leftmost peak). Transduction was detected by expression of CAR antibodies on the cell surface using flow cytometry. Figure 2B) Representative histograms show that BM MSCs (left) and CT MSCs (right) were transduced with retroviral vectors expressing CAR CD38, with 63.9% efficiency (blue graph) and 87.9% efficiency (blue graph; right peak) for BM MSCs compared to untransduced MSCs (red graph; left peak) and isotype (grey graph; leftmost peak). Transduction was detected using flow cytometry by expressing CAR antibodies on the cell surface. Figure 2C ) Representative histograms show that CT MSCs were transduced with a retroviral vector expressing fucosyltransferase 6 (FT6) (adds sugars to specific residues of proteins, increasing the adhesion potential of MSCs; it can bind to one or more CARs in MSCs) with an efficiency of 83.6% (blue graph; right peak) compared to untransduced MSCs (red graph; left peak) and isotype (grey graph; also left peak). Transduction was detected by the expression of sialyl-Lewis X (sLeX) and Lewis (LeX) residues (HECA) on their cell surface using flow cytometry. Figure 2D ) Representative histograms showing that CT MSCs at passage 5 were transduced with retroviral vectors co-expressing FT6 (left graph) and membrane-bound IL-21 (right graph), with 46.8% efficiency for FT6 and 67.9% efficiency for IL-21 (blue graph; right peak) compared to untransduced MSCs (red graph; left peak) and isotype (grey graph; left peak).

[0020] Figures 3A-3D .Efficiency of CRISPR Cas9 gene editing of immunosuppressive genes expressed in umbilical cord tissue (CT) MSCs. Figure 3A ) Representative histogram showing the knockout (KO) efficiency of CD47 gene editing targeting exon 2 in MSCs (blue; left peak) compared to Cas9 control (red; right peak), demonstrated by flow cytometry. Figure 3B ) DNA electrophoresis gel showing the knockout efficiency of CRISPR Cas9 gene editing of the CD47 gene in MSCs using guides targeting exon 1 and targeting exon 2, and cells, as well as PD-L2 (right panel) as a single guide in CT MSCs (blue), compared to a Cas9 control (red). Figure 3C ) Representative histograms showing the knockout efficiency of the immunosuppressive genes PD-L1 (left panel) and PD-L2 in CT MSCs assessed by flow cytometry (blue; mainly left peak) compared with the Cas9 control (red; mainly right peak). Figure 3D ) Representative histograms showing double knockout of PD-L1 / PD-L2 (mostly left peak), electroporated with Cas9 only (Cas9; mostly right peak) and used as control.

[0021] Figures 4A-4C Transduction and function of umbilical cord tissue (CT)-derived MSCs bearing CD40L. Figure 4A ) Representative histogram showing that CT MSCs were transduced with a CD40L-expressing retroviral vector with an efficiency of 87.1% (blue graph; mainly right peak) compared to non-transduced MSCs (red graph; mainly left peak) assessed by flow cytometry. Figure 4B ) Bar graph showing the consistency of MSCs transduced with CD40L maintained in culture. Figure 4C ) Suppressive effect of CT MSCs. Proliferation of purified T lymphocytes induced by CD3 / CD28 beads in the absence or presence of non-transduced MSCs or MSCs transduced at different ratios as assessed by flow cytometry.

[0022] Figure 5A-5B . Proliferation and functional studies of MSCs engineered by CRISPR Cas9 gene editing of immunosuppressive genes. Figure 5A : Cumulative population doubling level (cPD) of knockout (K) MSCs. MSC P4 (75,000) were seeded in 24-well plates using complete medium and expanded for 7 days, with the medium changed twice a week. After that, the MSC monolayer was released using trypLE, the cells were washed with complete medium and spun at 300g for 10 minutes. The cells were then resuspended in 1 ml of complete medium and counted using an automated counter using acridine orange / propidium iodide staining (AO / PI). The cPD after each passage was calculated by applying the following formula: 2PD = number of harvested cells / number of seeded cells; cPD = Σn2 (PD1 + PD2 + ::: + PDn), where PD refers to population doubling. Figure 5B : The immunosuppressive potential of MSC KO cells and Cas9 control cells was tested in vitro by measuring cytokine secretion by CD4+ cells (IFNg, IL-2, TNFa) after co-culture with CD4+ T cells. KO and Cas9 control MSCs were co-cultured with CD4+ T cells at a 1:1 ratio (MSC / CD4).

[0023] Description of Illustrative Embodiments

[0024] I. Definitions

[0025] As used in this specification, "one" or "a kind of" may refer to one or more / one or more. As used in the claims, when used with the word "including", the word "one" or "a kind of" may refer to one or more / one or more. As used herein, "another" may refer to at least a second or more. In addition, the terms "having", "including", "comprising" and "containing" are interchangeable, and those skilled in the art recognize that these terms are open terms. In specific embodiments, various aspects of the present disclosure may, for example, be "essentially composed of" or "composed of" one or more sequences of the present disclosure. Some embodiments of the present invention may consist of or essentially consist of one or more elements, method steps and / or methods of the present disclosure. It is contemplated that any method or composition described herein may be implemented relative to any other method or composition described herein. The scope of the present application is not intended to be limited to the specific embodiments of the methods, machines, manufactures, material compositions, means, methods and steps described in this specification. As used herein, the terms "or" and "and / or" are used to describe a plurality of components that are combined or mutually exclusive. For example, "x, y, and / or z" may mean "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y and z)," or "x or y or z." It is specifically contemplated that x, y, or z may be specifically excluded from an embodiment.

[0026] The use of the term "or" in the claims is intended to mean "and / or" unless explicitly indicated to refer to only alternatives or the alternatives are mutually exclusive, although the present disclosure supports a definition referring to only alternatives and "and / or." As used herein, "another" may refer to at least a second or more. The terms "approximately," "substantially," and "about" generally refer to plus or minus 5% of the stated value.

[0027] Throughout this specification, reference to "one embodiment," "an embodiment," "a specific embodiment," "a related embodiment," "an embodiment," "an additional embodiment," or "another embodiment," or combinations thereof, means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, in one or more embodiments, the particular features, structures, or characteristics may be combined in any suitable manner.

[0028] "Immune disorder," "immune-related disorder," or "immune-mediated disorder" refers to a disorder in which the immune response plays a key role in the development or progression of the disease. Immune-mediated disorders include autoimmune diseases, allograft rejection, graft-versus-host disease, and inflammatory and allergic conditions.

[0029] As used herein, the term "engineered" refers to artificially produced entities, including cells, nucleic acids, polypeptides, vectors, etc. In at least some cases, engineered entities are synthetic and include elements that do not exist naturally or are configured in the manner used in the present disclosure. With regard to MSCs, cells can be engineered because they have reduced expression of one or more endogenous genes and / or because they express one or more heterologous genes (e.g., synthetic antigen receptors and / or cytokines), in which case the engineering is all done artificially. With regard to antigen receptors, antigen receptors can be considered to be engineered because they contain multiple components that are genetically recombined to be configured in a manner not found in nature (e.g., in the form of fusion proteins of components that are not found so configured in nature).

[0030] As used herein, the term "large scale" refers to approximately up to 10 9 or more, including 10 10 10 11 An equal number of MSCs.

[0031] "Treatment" or medical treatment of a disease or condition refers to the implementation of a regimen that may include administering one or more drugs to a patient in an effort to alleviate the signs or symptoms of the disease. Desirable effects of treatment include reducing the rate of disease progression, improving or relieving the disease state, and alleviating or improving prognosis. Relief may occur before signs or symptoms of the disease or condition appear, or after they appear. Thus, "treatment" or "medical treatment" may include "prevention" or "preventing" a disease or unwanted condition. Furthermore, "treatment" or "medical treatment" does not require complete relief of signs or symptoms, does not require a cure, and specifically includes regimens that have only a minor effect on the patient.

[0032] As used in this application, the terms "therapeutic benefit" or "therapeutically effective" refer to any aspect of the well-being of a subject with respect to a medical treatment of the condition that promotes or enhances the well-being of the subject. This includes, but is not limited to, reducing the frequency or severity of signs or symptoms of the disease. For example, treatment of cancer may involve, for example, a reduction in tumor size, a reduction in tumor invasiveness, a reduction in the growth rate of the cancer, or the prevention of metastasis. Treatment of cancer may also refer to prolonging the survival of a subject with cancer.

[0033] "Subject" and "patient" or "individual" refer to humans or non-humans, such as primates, mammals, and vertebrates. In certain embodiments, the subject is a human.

[0034] As used herein, "mammals" are suitable subjects for the methods of the present invention. Mammals can be any member of the higher vertebrate class mammals, including humans; characterized by live birth, body hair, and mammary glands in females that secrete milk for feeding young. In addition, mammals are characterized by their ability to maintain a constant body temperature despite changes in climatic conditions. Examples of mammals are humans, cats, dogs, cows, mice, rats, horses, goats, sheep, and chimpanzees. Mammals may be referred to as "patients" or "subjects" or "individuals."

[0035] The term "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered to animals (e.g., humans) as needed. The preparation of pharmaceutical compositions comprising antibodies or other active ingredients will be known to those skilled in the art in light of this disclosure. In addition, for administration to animals (e.g., humans), it will be understood that the formulations should meet the sterility, pyrogenicity, general safety and purity standards required by the FDA Office of Biological Standards.

[0036] As used herein, "pharmaceutically acceptable carriers" include any and all aqueous solvents (e.g., water, alcohol / water solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc.), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters such as glycolate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, antioxidants, chelating agents, and inert gases), isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, fluids, and nutritional supplements, materials like these, and combinations thereof, as known to those of ordinary skill in the art. The pH and exact concentration of the various components in the pharmaceutical composition are adjusted according to well-known parameters.

[0037] As used herein, the "destruction" of a gene refers to the elimination or reduction of the expression of one or more gene products encoded by the subject gene in a cell compared to the expression level of the gene product in the absence of the destruction. Exemplary gene products include mRNA and protein products encoded by the gene. In some cases, the destruction is transient or reversible, and in other cases it is permanent. In some cases, although truncated or non-functional products can be produced, the destruction is the destruction of functional or full-length proteins or mRNAs. In some embodiments herein, relative to expression, gene activity or function is destroyed. Gene destruction is usually induced by artificial methods, i.e., by adding or introducing compounds, molecules, complexes or compositions, and / or by destroying the nucleic acid of the gene or inducing nucleic acids associated with the gene, such as at the DNA level. Exemplary methods of gene destruction include gene silencing, knocking down, knocking out and / or gene destruction techniques, such as gene editing. Examples include antisense techniques, such as RNAi, siRNA, shRNA and / or ribozymes, which generally result in a transient decrease in expression, and gene editing techniques that result in targeted gene inactivation or destruction, such as by inducing breakage and / or homologous recombination. Examples include insertion, mutation and deletion. This destruction usually results in inhibition and / or complete deletion of the expression of a normal or "wild-type" product of a gene encoding. Examples of such gene disruptions are insertion, frameshift and missense mutations, deletions, knock-ins and knockouts of genes or parts of genes, including the deletion of entire genes. This disruption can occur in the coding region, for example in one or more exons, resulting in failure to produce a full-length product, a functional product or any product, for example by inserting a stop codon. This disruption can also occur through the disruption of promoters or enhancers or other regions that affect transcriptional activation, thereby preventing transcription of the gene. Gene disruption includes gene targeting, including inactivating the targeted gene by homologous recombination.

[0038] As used herein, the term "heterologous" refers to a cell type or species different from that of the recipient. In certain cases, it refers to a gene or protein that is synthetic and / or not derived from MSCs. The term also refers to a synthetically derived gene or gene construct. For example, even if a cytokine is naturally produced by MSCs, the cytokine can be considered heterologous with respect to MSCs because the cytokine is synthetically derived, such as by genetic recombination, including being provided to the MSCs in a vector containing a nucleic acid sequence encoding the cytokine.

[0039] As used herein, the term "mesenchymal stem cell" or "mesenchymal stromal cell" or "MSC" refers to a multipotent stromal cell that can differentiate into a variety of cell types. In a specific embodiment, MSC has one or more characteristics. In a specific embodiment, MSC has expression of one or more of CD90, CD105, CD73, CD44 and HLA-I, and / or lacks expression or reduced expression of (e.g., with respect to hematopoietic cells) lineage markers (e.g., CD31, CD45, CD3, CD19, HLA-DR and / or CD14).

[0040] The present disclosure relates to a novel method for large-scale expansion, CAR transduction, cytokine expression and gene editing for MSC. The method allows the expansion of peripheral blood-derived, cord blood-derived or stem cell-derived MSCs (as an example) to be amplified to a larger number and transduced to redirect its specificity to tumor antigens (and optionally expressing cytokine genes). The function of MSCs is further improved by deleting one or more genes (as some examples) that are involved in the dysfunction of cell exhaustion and tumor induction.

[0041] In certain embodiments, the present disclosure comprises combined CAR transduction and deletion of single or multiple genes in human MSCs, which contribute to the improved function of the cells and resistance to the tumor microenvironment. In particular, large-scale and GMP-grade protocols disclose the production of MSCs that allow for treatment. Embodiments of the present disclosure include improved patient care using novel immunotherapy methods that enhance the function of a patient's own MSCs or adoptively transferred MSCs.

[0042] II. Methods

[0043] Embodiments of the present disclosure relate to methods for producing engineered MSCs, particularly on a large scale. In particular embodiments, the methods utilize a specific parameter or a combination of specific parameters to produce certain types of engineered MSCs, wherein the parameters include a certain concentration of reagents, certain types of MSCs, a certain duration of one or more steps, certain types of cell modification mechanisms, or a combination thereof. Those skilled in the art will recognize that, although optimal variables are described herein, there are variations of the methods that will still produce an appropriate amount of engineered MSCs, and these are also included herein.

[0044] The method generally involves a series of steps, and in a specific embodiment, the series comprises the expansion of MSCs, the engineering of MSCs in one, two or more aspects, and the expansion of the engineered cells produced, followed by an optional analysis step and / or an optional application step to the individual. In a specific embodiment, the engineering comprises the following (1) modifying the cells to express heterologous proteins, such as engineered antigen receptors and / or cytokines (and / or fucosyltransferase 6 and / or membrane-bound IL-21 and / or CD40L) and (2) modifying the cells to have reduced expression (knockdown) or eliminated expression (knockout) of one or more endogenous genes in MSCs. In some cases, (1) occurs before (2), and in other cases, (2) occurs before (1). Although the cells can be modified to have reduced expression or eliminated expression by any means, in a specific embodiment, the modification is performed by CRISPR.

[0045] The initial step of the method can be the expansion of MSCs, which allows increasing the number of MSCs for final modification. MSCs can be obtained from a fresh source or from a storage or commercially available source. Although MSCs can be of any type, in a specific embodiment, MSCs are derived from umbilical cord blood tissue, peripheral blood, bone marrow, adipose tissue tumors, or a mixture thereof. In a specific case, MSCs are derived from umbilical cord tissue or bone marrow. In a specific embodiment, the starting culture of MSCs used in the expansion step includes at least 5-100x10 6 cells, and in some cases 1x10 9 Thus, in certain cases, the number of MSCs used to initiate the protocol is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100x10 6 A range of numbers of cells may be used in any step of the method, including 5-100, 5-90, 5-75, 5-50, 5-25, 5-10, 10-100, 10-90, 10-75, 10-60, 10-50, 10-25, 25-100, 25-90, 25-75, 25-50, 50-100, 50-90, 50-75, 75-100, 75-90, or 90-100 x 10 6 cells, and any range derivable therefrom.

[0046] In certain embodiments, prior to initiating the expansion step in culture, MSCs are subjected to depletion of specific unwanted cells that may be present with the mixed cell population. The depletion step can exploit the presence of certain markers on unwanted cells as a means of removing them from the MSC population. As an example of a method to achieve this, immunomagnetic beads (with antibodies to markers associated with unwanted cells) can be used to deplete cells, thereby generating an enriched MSC population.

[0047] In certain embodiments, the culture medium in which the expansion step is performed may lack cytokines. The expansion step may occur at a certain temperature, such as about 35°C-38°C, including 35°C, 36°C, 37°C or 38°C. The expansion step may occur at a certain level of oxygen, such as 3%-7% CO2; in specific embodiments, the expansion step occurs at 3%, 4%, 5%, 6% or 7% CO2. The expansion step may last for a specific duration, such as a certain number of days. In certain embodiments, the expansion step lasts for 2, 3, 4, 5, 6, 7 days or more, but in certain cases, the expansion step lasts for 2-7, 3-7, 2-6, 3-6, 4-7, 4-6, 4-5, 5-6, 5-7 or 6-7 days. In certain embodiments, the culture medium in the expansion step may or may not be changed during the expansion process, but in certain embodiments, the culture medium is replaced. The culture medium may be replaced with a culture medium that has been changed to the same culture medium composition as before or a different culture medium composition. In certain aspects, the expansion step occurs in a bioreactor, such as a gas permeable bioreactor, such as 100M or In certain aspects, the bioreactor is a gas permeable bioreactor. In certain aspects, the gas permeable bioreactor is 100M or In some aspects, the expansion (stimulation) step is performed in a specific amount of culture medium (eg, 3-5 L of culture medium, eg, 3, 3.5, 4, 4.5, or 5 L).

[0048] About 2, 3, 4, 5, 6, 7 or 8 days after the MSC expansion begins, the expanded MSC can be subjected to any kind of modification. The first modification can be the transduction or transfection of MSC to express one or more heterologous antigen receptors, although the first modification in some cases is the expression of one or more endogenous genes that destroy MSC. When the first modification is the expression of one or more endogenous genes that destroy MSC, the subsequent modification can be the expression of one or more endogenous genes that destroy MSC. When the first modification is the expression of one or more endogenous genes that destroy MSC, the subsequent modification can be the transduction or transfection of MSC to express one or more heterologous antigen receptors. In a specific embodiment, MSC is engineered to express one or more heterologous cytokines, and this step can occur at any time.

[0049] In a specific embodiment, the MSC amplified by transduction or transfection is to contain heterologous antigen receptor genes before the cell is gene-edited to destroy the expression of one or more endogenous genes. In a specific embodiment, the cell is transduced or transfected with a specific vector, which contains an expression construct encoding one or more chimeric antigen receptors, one or more T cell receptors or a combination thereof. The carrier can be any kind, including at least nanoparticles, plasmids, slow virus vectors, retroviral vectors, adenovirus vectors, adenovirus-associated vectors, etc. MSC can be transfected or transduced with a vector that allows MSC to express a variety of heterologous proteins (e.g., one or more heterologous antigen receptors, suicide genes, and one or more cytokines, such as one or more heterologous cytokines selected from IL-7, IL-2, IL-15, IL-12, IL-18, IL-21, IL-22, and combinations thereof). Although the genes of a variety of heterologous proteins can be present on the same carrier, in some cases they are present on multiple carriers. Once the cells have been transduced or transfected, they are modified and can be tested for the expression of one or more heterologous proteins, which can occur 1, 2, 3 or more days after transfection / transduction. When testing an aliquot from a population of modified MSCs, the testing may or may not occur prior to further modification, such as prior to gene editing of the MSCs.

[0050] In about 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 days after the amplification of MSC begins, the modified MSC can be subjected to the method of gene editing. The gene editing step can be performed within 1, 2, 3 days or longer days after the transfection / transduction step. The gene editing of modified (transfected or transduced) MSC can be performed by any suitable method, but in a specific embodiment, the gene editing of modified MSC is performed by CRISPR method. Therefore, in a specific embodiment, the modified cells are exposed to an appropriate amount of Cas9 and guide RNA. In the case where the expression of more than one gene of MSC is to be destroyed, there may be a group of guide RNAs, which include one or more sequence-specific guide RNAs for each desired gene to be edited. In a specific embodiment, MSC is subjected to two different electroporation steps, which are separated in time by 1, 2, 3 days or more. In this case, the first electroporation step includes targeting one or more genes, and the second or subsequent electroporation step includes targeting one or more genes, which are genes different from the genes in the first electroporation step. In some cases, there are consecutive electroporation steps in addition to two electroporation steps, including 3, 4, 5 or more additional electroporation steps. In any case where multiple electroporation steps are used, subsequent electroporation may or may not only occur after a specific duration, such as after only 1, 2, 3, 4 or more days from the previous electroporation step.

[0051] In certain embodiments, MSCs first undergo a gene editing step followed by a transduction or transfection step to include one or more heterologous antigen receptor genes.

[0052] After gene editing and transformation / transduction of MSCs, the MSCs may or may not be subjected to a second expansion step to increase the number of modified gene-edited MSCs. In a particular embodiment, the second expansion step in the method may be substantially the same as the first expansion step in the method, although in alternative embodiments the second expansion step is different from the first expansion step, such as having a different culture medium, a different exogenously added compound, a different duration of culture / amplification, a different expansion bottle (e.g., GREX or WAVE, etc.), or a combination thereof, etc.

[0053] After a specific duration of the second expansion step, the cells can be utilized, analyzed, stored, etc. In specific embodiments, the cells are analyzed for functionality, cytotoxicity, in vivo activity, etc. For example, the cells can be analyzed for (1) the ability of a heterologous antigen receptor to bind its target antigen; (2) expression of an edited gene or its deletion to confirm knockdown or knockout of expression, or (3) both. In specific cases, for example, the cells are subjected to mass spectrometry and / or RNA sequencing. The anti-cancer activity of the cells can be analyzed in vitro and / or in vivo.

[0054] In certain embodiments, the generated MSCs are stored, including, for example, cryopreserved. For example, the MSCs can be cryopreserved for use by the individual from whom the starting MSCs were obtained, or the MSCs can be cryopreserved for use by an individual different from the individual from whom the starting MSCs were obtained.

[0055] III. Specific implementation plan

[0056] A specific embodiment of the method of generating MSCs may be as follows.

[0057] MSC cell expansion and transduction

[0058] Mesenchymal stem cells / mesenchymal stromal cells (MSCs) from bone marrow (BM) and umbilical cord tissue (CBt) were expanded in complete medium until they reached 80% confluence, and the medium contained 5% platelet lysate, 1% L-glutamine, 2U / ml heparin and 1% antibiotics (penicillin-streptomycin) supplemented. After reaching 80% confluence, MSCs were trypsinized for 5 minutes using 1% TrypLe Express enzyme, washed with PBS and counted.

[0059] MSC can be transduced (including retroviral transduction) to express one or more CARs, one or more synthetic TCRs, one or more cytokine genes, CD40 ligands, homing receptors, death receptors such as TRAIL or FAS ligands, etc., or a combination of these genes. The transduction step can be performed on MSCs with lower passages (1 to 4 generations). Recombinant connexin transduction plates are prepared by culturing non-tissue culture plates containing 1% recombinant connexin (retronectin) diluted in PBS with 1ml for 5 hours at 37°C. The recombinant connexin plate is then aspirated and complete medium without antibiotics is added to the wells. The plate containing the culture medium is incubated for 10 minutes. The culture medium is then replaced with retroviral supernatant and centrifuged at 2000g and 32°C for 2 hours. The retroviral supernatant is then replaced with fresh retroviral supernatant and cells are added. The plate is shaken at 37°C and 5% CO2 at a speed of 20rpm for 50 minutes, and then left to stand at 37°C and 5% CO2. After 24 hours, the supernatant is removed and new fresh complete medium is added to the plate. MSCs were cultured at 1.5 x 10 per 100 mm dish. 5 The cells are plated on recombinant connexin transduction plates at a density of 10 cells / mL. After 2-3 days (post-transduction), the transduced MSCs are trypsinized, centrifuged, and expanded in complete medium. At this point, flow cytometry should be used to assess the transduction efficiency of the MSCs.

[0060] MSC cell expansion and CRISPR gene editing

[0061] Mesenchymal stem cells / mesenchymal stromal cells (MSCs) from bone marrow (BM) and umbilical cord tissue (CBt) were expanded in complete medium until they reached 80% confluence, and the medium contained 5% platelet lysate, 1% L-glutamine, 2U / ml heparin and 1% antibiotics (penicillin-streptomycin) supplemented. After reaching 80% confluence, MSCs were trypsinized for 5 minutes using 1% TrypLe Express enzyme, washed with PBS and counted.

[0062] For knocking out genes in MSCs using CRISPR Cas9 gene editing, MSCs of lower passages (passages 1 to 4) were used. The cells were trypsinized for 5 minutes using 1% TrypLe Express enzyme, washed with PBS and counted. In specific cases, up to two or three genes can be edited simultaneously in one electroporation step. If more than two genes are targeted, let the cells rest for 2-3 days after the first electroporation step and then perform a second CRISPR-Cas9+ electroporation with the desired gRNA. (For details on CRISPR Cas9 applications, see below). In specific embodiments, up to five genes can be knocked out in the same MSC cell, and in specific cases, this does not occur in the same reaction on the same day, but in different reactions and days.

[0063] MSC cell expansion, CAR transduction and CRISPR gene editing

[0064] Mesenchymal stem cells / mesenchymal stromal cells (MSCs) from bone marrow (BM) and umbilical cord tissue (CBt) were expanded in complete medium until 80% confluence was reached, and the medium contained 5% platelet lysate, 1% L-glutamine, 2U / ml heparin and 1% antibiotics (penicillin-streptomycin) supplemented. After reaching 80% confluence, MSCs were trypsinized for 5 minutes using 1% TrypLeExpress enzyme, washed with PBS and counted.

[0065] MSC can be transduced (including retroviral transduction) to express one or more CARs, one or more synthetic TCRs, one or more cytokine genes, CD40 ligands, homing receptors, death receptors such as TRAIL or FAS ligands, etc., or a combination of these genes. The transduction step can be performed on MSCs of lower passages (1st to 4th generations). Recombinant connexin transduction plates are prepared by culturing non-tissue culture plates containing 1% recombinant connexin diluted in PBS with 1ml for 5 hours at 37°C. The recombinant connexin plates are then aspirated and complete medium without antibiotics is added to the wells. The plates containing the culture medium are incubated for 10 minutes. The culture medium is then replaced with retroviral supernatant and centrifuged at 2000g and 32°C for 2 hours. Next, the retroviral supernatant is replaced with fresh retroviral supernatant and cells are added. The plate is shaken at 37°C and 5% CO2 at a speed of 20rpm for 50 minutes, and then left to stand at 37°C and 5% CO2. After 24 hours, the supernatant is removed and new fresh complete medium is added to the plate. MSCs were cultured at 1.5 x 10 per 100 mm dish. 5The cells are plated on recombinant connexin transduction plates at a density of 100 cells / mL. After 2-3 days (post-transduction), the transduced MSCs are trypsinized, centrifuged, and expanded in complete medium. At this point, flow cytometry should be used to assess the transduction efficiency of the MSCs.

[0066] If CRISPR-Cas9 gene editing is required, 72-96 hours after the CAR transduction step, MSCs are trypsinized again for 5 minutes using 1% TrypLeExpress enzyme, washed with PBS and counted. Up to two genes can be edited simultaneously in one electroporation step. If more than two genes are targeted, the cells can be rested for 2-3 days after the first electroporation step and then a second CRISPR-Cas9+ electroporation with the desired gRNA can be performed. (For more details on CRISPR Cas9 applications, see below).

[0067] Note that it is also possible to perform the CRISRP gene editing step first and then perform CAR transduction 2-3 days later.

[0068] One example of CRISPR gene editing that can be applied to MSCs is provided below, although any one or more variables may be altered.

[0069] 1. crRNA pre-complex and electroporation (Lonza4D) (for 5-30x10 6 MSCs)

[0070] Step 1: Make crRNA+tracrRNA duplex

[0071]

[0072] The starting concentration of crRNA and tracrRNA was 200uM. The final concentration after mixing them in equimolar concentrations was 100uM.

[0073] a. Mix by pipetting and centrifuge.

[0074] b. Incubate at 95°C in a thermal cycler for 5 minutes.

[0075] c. Cool to room temperature on the workbench

[0076] Step 2: Assemble crRNA:tracrRNA duplex and Cas9 nuclease

[0077]

[0078]

[0079]

[0080] a. Mix by pipetting and centrifuge.

[0081] b. Incubate the mixture at room temperature for 15 minutes.

[0082] Step 3: Combine crRNA #1 and crRNA #2 from step 3

[0083]

[0084] Step 4: Perform electroporation

[0085] a. Prepare culture plates with culture medium (preferably without antibiotics)

[0086] b. Prepare 5x10 6 cells (washed twice with PBS to remove FBS) and resuspended in 100 ul P3 Primary Cell Nucleofector Solution before use.

[0087] c. Mix the cell suspension and RNP (final Cas9 concentration is 4.6uM, gRNA concentration is 4uM), transfer to the nucluocuvette and cover it.

[0088] d. The electroporation procedure was EO-115, and the cells were then added to the culture plate and allowed to recover in a 37°C incubator.

[0089] e. Up to 5E+106-X units (Catalog No.: AAF-1002X) (20ul of the previous product is sufficient, see the final concentration above)

[0090] volume crRNA#1,2+tracrRNA+cas9 (step 3) 20ul Cell suspension 100ul Total volume 120ul

[0091] f. For up to 30x10 6 For electroporation, use 1 ml LV Kit L Unit (Catalog #: V4LC-2002).

[0092] g. For up to 100x10 6 or more electroporation, use 1 ml LV Kit L Unit (Catalog #: AAF-1002L).

[0093] H. Calculate the total amount of RNP complexes required by dividing the total cell number by 5x106 and then multiplying by the final number of RNP complexes from step 3.

[0094] i. Example: If the number of cells is 30x10 6 , 30x10 6 / 5x10 6 =6, then use 6x20ul=120ul

[0095] ii. Example: If the number of cells is 100x10 6 , 100x10 6 / 5x10 6 =20, then 20x20ul=400ul

[0096] CRISPR CAS9: Small-scale protocol (starting cell population 0.15-3x10 6 )

[0097] 1. sgRNA-Cas9 pre-complex and electroporation (Neon-Thermo Fisher)

[0098] a. Design and use 1 or 2 sgRNAs for each gene, perform 1.5ug cas9 (PNA Bio) and 500ng sgRNA (total of all sgRNAs) reaction for each gene and incubate on ice for 20 minutes.

[0099] b. After 20 minutes, add 150,000 MSC cells resuspended in R buffer (included in the Neon electroporation kit (Invitrogen), the total volume including RNP complexes and cells should be 14ul) and electroporate using the Neon transfection system with a 10ul electroporation tip.

[0100] c. For MSC cells, the electroporation conditions were 1600 V, 10 ms, and 3 pulses. The cells were then added to a culture plate with culture medium and recovered in a 37°C incubator.

[0101] 2.crRNA pre-complexation and electroporation (Neon-Thermo Fisher)

[0102] Step 1: Make crRNA+tracrRNA duplex

[0103]

[0104] The starting concentration of crRNA and tracrRNA was 200uM. The final concentration after mixing them in equimolar concentrations was 44uM.

[0105] d. Mix by pipetting and centrifuge.

[0106] e. Incubate at 95 °C for 5 minutes in a thermal cycler.

[0107] f. Cool to room temperature on bench top.

[0108] Step 2: Prepare Cas9 nuclease

[0109]

[0110] Step 3: Assemble crRNA:tracrRNA duplex and Cas9 nuclease

[0111]

[0112]

[0113]

[0114] a. Mix by pipetting and centrifuge.

[0115] b. Incubate the mixture at room temperature for 15 minutes.

[0116] Step 4: Combine crRNA #1 and crRNA #2 from step 3

[0117] volume crRNA#1+tracrRNA+cas9 (step 3) 2.25ul crRNA#2+tracrRNA+cas9 (step 3) 2.25ul Total volume 4.5ul

[0118] Step 5: Perform electroporation

[0119] Prepare 250,000 cells per well and resuspend in 7.5ul T buffer before use.

[0120] The electroporation conditions were 1600 V, 10 ms, and 3 pulses. The cells were then added to the culture plate and recovered in a 37°C incubator.

[0121] IV. Heterologous Antigen Receptors

[0122] The MSC of the present disclosure may be genetically engineered to express one or more heterologous antigen receptors, such as engineered TCR, CAR, chimeric cytokine receptor, chemokine receptor, combinations thereof, etc. Heterologous antigen receptors are produced by artificial synthesis. In a particular embodiment, MSC is modified to express one or more CARs and / or TCRs, which have antigen specificity for cancer antigens. Multiple CARs and / or TCRs may be added to MSCs, such as CARs and / or TCRs for two or more different antigens. In some aspects, immune cells are engineered to express CARs or TCRs by knocking in CARs or TCRs at specific loci, such as by using CRISPR.

[0123] Although CRISPR is used to edit MSCs in particular, alternative suitable modification methods are known in the art. See, for example, Sambrook and Ausubel above. For example, cells can be transduced using the transduction techniques described in Heemskerk et al., 2008 and Johnson et al., 2009 to express TCRs with antigen-specificity for cancer antigens. In some embodiments, cells include one or more nucleic acids encoding one or more antigen receptors introduced by genetic engineering, and genetically engineered products of such nucleic acids. In some embodiments, nucleic acids are heterologous, that is, they are generally not present in cells or samples obtained from the cell, such as nucleic acids obtained from another organism or cell, which are, for example, generally not found in engineered cells and / or organisms derived from such cells. In some embodiments, nucleic acids are not naturally occurring, such as nucleic acids not present in nature (e.g., chimeric).

[0124] In some embodiments, CAR comprises an extracellular antigen recognition domain that specifically binds to an antigen. In some embodiments, the antigen is a protein expressed on the surface of a cell (including a cancer cell, such as a cancer cell in an individual in need of treatment). In some embodiments, CAR is a TCR-like CAR, and the antigen is a processed peptide antigen, such as a peptide antigen of an intracellular protein, which, like TCR, is recognized on the cell surface in the context of a major histocompatibility complex (MHC) molecule.

[0125] Exemplary antigen receptors (including CARs and recombinant TCRs) and methods of engineering and introducing the receptors into cells include, for example, those described in International Patent Application Publication Nos. WO200014257, WO2013126726, WO2012 / 129514, WO2014031687, WO2013 / 166321, WO2013 / 071154, WO2013 / 123061, U.S. Patent Application Publication Nos. US2002131960, US2013287748, US20130149337, U.S. Patent Nos. 6,451,995, 7,446,190, 8,252,592, 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353 and 8,479,118, and European Patent Application No. EP2537416 and / or those described in Sadelain et al., 2013; Davila et al., 2013; Turtle et al., 2012; Wu et al., 2012. In some aspects, the genetically engineered antigen receptor includes a CAR as described in U.S. Patent No. 7,446,190, and those described in International Patent Application Publication No. WO / 2014055668A1.

[0126] A. Chimeric Antigen Receptor

[0127] In some embodiments, CAR includes: a) one or more intracellular signaling domains, b) a transmembrane domain, and c) an extracellular domain comprising one or more antigen binding regions. In the case where the extracellular domain comprises two or more antigen binding regions, the two or more antigens are different antigens, including different antigens expressed on the surface of the same cell or the same type of cell in some cases.

[0128] In some embodiments, the engineered antigen receptor includes CAR, including activation or stimulatory CAR, costimulatory CAR (see WO2014 / 055668) and / or inhibitory CAR (iCAR, see Fedorov et al., 2013). CAR generally includes an extracellular antigen (or ligand) binding domain connected to one or more intracellular signal transduction components (in some aspects through a joint and / or one or more transmembrane domains). Such molecules generally simulate or approximate the signal caused by a natural antigen receptor, the signal caused by such a receptor combined with a costimulatory receptor, and / or the signal caused only by a costimulatory receptor.

[0129] Certain embodiments of the present disclosure relate to the use of nucleic acids, including nucleic acids encoding antigen-specific CAR polypeptides (including CARs (hCARs) that have been humanized to reduce immunogenicity, which include intracellular signaling domains, transmembrane domains, and extracellular domains comprising one or more signal transduction motifs). In certain embodiments, CAR can recognize an epitope contained in a shared space between one or more antigens. In certain embodiments, the binding region may include a complementary determining region of a monoclonal antibody, a variable region of a monoclonal antibody, and / or an antigen binding fragment thereof. In another embodiment, the specificity is derived from a peptide (e.g., a cytokine) that binds to a receptor.

[0130] It is expected that human CAR nucleic acid can be a human gene for enhancing the cellular immunotherapy of human patients. In a specific embodiment, the present invention includes full-length CAR cDNA or coding region. Antigen binding region or domain may include a fragment of VH and VL chains of a single-chain variable fragment (scFv) derived from a specific human monoclonal antibody, such as those described in U.S. Patent 7,109,304, which is incorporated herein by reference. The fragment may also be any number of different antigen-binding domains of human antigen-specific antibodies. In a more specific embodiment, the fragment is an antigen-specific scFv encoded by a sequence optimized for human codon usage for expression in human cells.

[0131] The arrangement can be a multimer, such as a diabody or a multimer. The multimer is most likely formed by cross-pairing the variable parts of the light chain and the heavy chain into a diabody. The hinge portion of the construct can have a variety of alternatives, from complete deletion to maintaining the first cysteine, to proline instead of serine replacement, truncated to the first cysteine. The Fc portion can be deleted. Any stable and / or dimerized protein can achieve this purpose. Only one Fc domain can be used, such as the CH2 or CH3 domain of a human immunoglobulin. The hinge region, CH2 region, and CH3 region of a human immunoglobulin modified to improve dimerization can also be used. It is also possible to use only the hinge portion of an immunoglobulin. A portion of CD8α can also be used.

[0132] In some embodiments, the CAR nucleic acid comprises a sequence encoding other co-stimulatory receptors (e.g., a transmembrane domain and a modified CD28 intracellular signaling domain). Other co-stimulatory receptors include, but are not limited to, one or more of CD28, CD27, OX-40 (CD134), DAP10, DAP12, and 4-1BB (CD137). In addition to the main signal triggered by CD3ζ, other signals provided by the human co-stimulatory receptors inserted into the human CAR are also important for the complete activation of MSCs and can help improve the in vivo persistence and the therapeutic success of adoptive immunotherapy.

[0133] In some embodiments, CAR is constructed in a manner specific to a specific antigen (or marker or ligand), the specific antigen being, for example, an antigen expressed in a specific cell type to be targeted by adoptive therapy, such as a cancer marker, and / or an antigen intended to induce an inhibitory response, such as an antigen expressed on a normal or non-diseased cell type. Therefore, CAR generally includes one or more antigen binding molecules, such as one or more antigen binding fragments, domains or parts, or one or more antibody variable domains, and / or antibody molecules in its extracellular portion. In some embodiments, CAR includes one or more antigen binding portions of an antibody molecule, such as a single-chain antibody fragment (scFv) derived from a variable heavy chain (VH) and a variable light chain (VL) of a monoclonal antibody (mAb).

[0134] In certain embodiments of chimeric antigen receptors, the antigen-specific portion of the receptor (which may be referred to as an extracellular domain comprising an antigen binding region) comprises a tumor-associated antigen or a pathogen-specific antigen binding domain. Antigens include carbohydrate antigens recognized by pattern recognition receptors (e.g., Dectin-1). Tumor-associated antigens can be of any kind, as long as they are expressed on the cell surface of tumor cells. Exemplary embodiments of tumor-associated antigens include CD19, CD20, carcinoembryonic antigen, alpha-fetoprotein, CA-125, MUC-1, CD56, EGFR, c-Met, AKT, Her2, Her3, epithelial tumor antigens, melanoma-associated antigens, mutated p53, mutated ras, etc. In certain embodiments, when there is a small amount of tumor-associated antigens, CAR can be co-expressed with cytokines to improve persistence. For example, CAR can be co-expressed with one or more cytokines such as IL-7, IL-2, IL-15, IL-12, IL-18, IL-21, or a combination thereof.

[0135] The sequence of the open reading frame encoding the chimeric receptor may be obtained from a genomic DNA source, a cDNA source, or may be synthesized (e.g., via PCR) or a combination thereof. Depending on the size of the genomic DNA and the number of introns, it may be desirable to use cDNA or a combination thereof, as introns have been found to stabilize mRNA. In addition, it may be further advantageous to use endogenous or exogenous non-coding regions to stabilize mRNA.

[0136] It is contemplated that the chimeric construct can be introduced into immune cells as naked DNA or in a suitable vector. Methods for stably transfecting cells using naked DNA by electroporation are known in the art. See, e.g., U.S. Patent No. 6,410,319. Naked DNA generally refers to DNA encoding a chimeric receptor contained in a plasmid expression vector in a suitable orientation for expression.

[0137] In some cases, a viral vector (e.g., a retroviral vector, an adenoviral vector, an adeno-associated viral vector, or a lentiviral vector) can be used to introduce the chimeric construct into an immune cell. Suitable vectors for use according to the methods of the present disclosure are non-replicative in immune cells. Many viral-based vectors are known in which the copy number of the virus maintained in the cell is low enough to maintain the viability of the cell, such as vectors based on HIV, SV40, EBV, HSV, or BPV.

[0138] In some aspects, antigen-specific binding or recognition components are connected to one or more transmembrane and intracellular signaling domains. In some embodiments, CAR includes a transmembrane domain fused to the extracellular domain of CAR. In one embodiment, a transmembrane domain naturally associated with one of the domains in CAR is used. In some cases, the transmembrane domain is selected or modified by amino acid replacement to avoid such domains from binding to the transmembrane domains of the same or different surface membrane proteins, so as to minimize the interaction with other members of the receptor complex.

[0139] In some embodiments, the membrane-spanning domain is derived from natural sources or from synthetic sources. If the source is natural, the domain is derived from any membrane-bound protein or membrane-spanning protein in some aspects. The membrane-spanning region includes those derived from the following (i.e., at least including one or more membrane-spanning regions): α, β or ζ chains of T cell receptors, CD28, CD3ζ, CD3ε, CD3γ, CD3δ, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, ICOS / CD278, GITR / CD357, NKG2D and DAP molecules. Alternatively, in some embodiments, the membrane-spanning domain is synthetic. In some aspects, the synthetic membrane-spanning domain mainly comprises hydrophobic residues, such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of the synthetic membrane-spanning domain.

[0140] In certain embodiments, the platform technology disclosed herein for genetically modifying immune cells (e.g., MSCs) includes (i) non-viral gene transfer using an electroporation device (e.g., a nucleofector), (ii) CARs that signal through an endodomain (e.g., CD28 / CD3-ζ, CD137 / CD3-ζ, or other combinations), (iii) CARs with variable lengths of an extracellular domain that connects the antigen recognition domain to the cell surface, and in some cases (iv) CARs derived from K562 to enable robust and digital expansion of the CAR +Artificial antigen presenting cells (aAPC) of immune cells (Singh et al., 2008; Singh et al., 2011).

[0141] T cell receptor (TCR)

[0142] In some embodiments, the genetically engineered antigen receptor includes a recombinant TCR and / or a TCR cloned from a naturally occurring T cell."T cell receptor" or "TCR" refers to a molecule comprising variable α and β chains (referred to as TCRα and TCRβ, respectively) or variable γ and δ chains (referred to as TCRγ and TCRδ, respectively), and capable of specifically binding to an antigenic peptide bound to an MHC receptor. In some embodiments, TCR is in the αβ form.

[0143] Typically, TCRs in the form of αβ and γδ are usually similar in structure, but the T cells expressing them may have different anatomical locations or functions. TCRs can be found on the cell surface or in a soluble form. Typically, TCRs are found on the surface of T cells (or T lymphocytes), and are generally responsible for identifying antigens bound to major histocompatibility complex (MHC) molecules. In some embodiments, TCRs may also include constant domains, transmembrane domains, and / or short cytoplasmic tails (see, e.g., Janeway et al., 1997). For example, in some aspects, each chain of TCR may have an N-terminal immunoglobulin variable domain, an immunoglobulin constant domain, a transmembrane region, and a short cytoplasmic tail at the C-terminus. In some embodiments, TCRs are associated with the invariant proteins of the CD3 complexes involved in mediating signal transduction. Unless otherwise indicated, the term "TCR" should be understood to encompass its functional TCR fragments. The term also encompasses complete or full-length TCRs, including TCRs in the form of αβ or γδ.

[0144] Therefore, for the purposes of this article, the TCR referred to includes any TCR or functional fragment, such as the antigen binding portion of a TCR that binds to a specific antigenic peptide (i.e., an MHC-peptide complex) bound to an MHC molecule. The "antigen binding portion" or "antigen binding fragment" of a TCR (which can be used interchangeably) refers to a molecule that contains a portion of the structural domain of a TCR but binds to an antigen (e.g., an MHC-peptide complex) bound to a full-length TCR. In some cases, the antigen binding portion comprises a variable domain of a TCR, such as a variable α chain and a variable β chain of a TCR, which is sufficient to form a binding site that binds to a specific MHC-peptide complex, such as typically each chain comprising three complementary determining regions.

[0145] In some embodiments, the variable domains of the TCR chains associate to form a loop or complementary determining region (CDR) similar to an immunoglobulin, which confers antigen recognition and determines peptide specificity by forming a binding site for the TCR molecule and determining peptide specificity. Typically, like immunoglobulins, CDRs are separated by framework regions (FRs) (see, e.g., Jores et al., 1990; Chothia et al., 1988; Lefranc et al., 2003). In some embodiments, CDR3 is the main CDR responsible for recognizing processed antigens, although it has also been shown that the CDR1 of the α chain interacts with the N-terminal portion of the antigenic peptide, while the CDR1 of the β chain interacts with the C-terminal portion of the peptide. CDR2 is considered to recognize MHC molecules. In some embodiments, the variable region of the β chain may include an additional hypervariable (HV4) region.

[0146] In some embodiments, the TCR chain comprises a constant domain. For example, like an immunoglobulin, the extracellular portion of the TCR chain (e.g., an alpha chain, a beta chain) can comprise two immunoglobulin domains, namely a variable domain at the N-terminus (e.g., a V chain and a V chain). a or Vp; usually amino acids 1 to 116 based on Kabat numbering, Kabat et al., "Sequences of Proteins of Immunological Interest, US Dept. Health and Human Services, Public Health Service National Institutes of Health, 1991, 5 th ed.), and the constant domains adjacent to the cell membrane (e.g., the α chain constant domain or C a , typically amino acids 117 to 259 based on Kabat, and a beta chain constant domain or Cp, typically amino acids 117 to 295 based on Kabat). For example, in some cases, the extracellular domain of a TCR formed by two chains comprises two membrane proximal constant domains and two membrane distal variable domains comprising CDRs. The constant domain of the TCR domain comprises a short linker sequence in which cysteine ​​residues form a disulfide bond, thereby forming a connection between the two chains. In some embodiments, the TCR may have additional cysteine ​​residues in each of the alpha and beta chains, such that the TCR comprises two disulfide bonds in the constant domain.

[0147] In some embodiments, the TCR chain may include a transmembrane domain. In some embodiments, the transmembrane domain is positively charged. In some cases, the TCR chain includes a cytoplasmic tail. In some cases, the structure allows TCR to associate with other molecules (e.g., CD3). For example, a TCR containing a constant domain with a transmembrane region can anchor the protein in the cell membrane and associate with the invariant subunit of the CD3 signal transduction device or complex.

[0148] Generally, CD3 is a multiprotein complex, which can have three different chains (γ, δ and ε) and ζ chain in mammals. For example, in mammals, the complex can contain a homodimer of CD3γ chain, CD3δ chain, two CD3ε chains and CD3ζ chain. CD3γ, CD3δ and CD3ε chains are highly correlated cell surface proteins of the immunoglobulin superfamily comprising a single immunoglobulin domain. The transmembrane region of CD3γ, CD3δ and CD3ε chains is negatively charged, which is a feature that allows these chains to associate with positively charged T cell receptor chains. The intracellular tails of CD3γ, CD3δ and CD3ε chains each contain a conserved motif, referred to as tyrosine-based immunoreceptor activation motifs or ITAMs, and each CD3ζ chain has three. Generally, ITAMs are related to the signal transduction ability of TCR complexes. These auxiliary molecules have negatively charged transmembrane regions and play a role in propagating signals from TCR to cells. CD3- and ζ- chains form so-called T cell receptor complexes together with TCR.

[0149] In some embodiments, TCR can be a heterodimer of two chains α and β (or optionally γ and δ), or it can be a single-chain TCR construct. In some embodiments, TCR is a heterodimer comprising two separate chains (α and β chains or γ and δ chains), which are, for example, connected by one or more disulfide bonds. In some embodiments, the TCR for the target antigen (e.g., cancer antigen) is identified and introduced into the cell. In some embodiments, the nucleic acid encoding TCR can be obtained from a variety of sources, such as by polymerase chain reaction (PCR) amplification of publicly available TCR DNA sequences. In some embodiments, TCR is obtained from biological sources, such as obtained from cells, such as obtained from T cells (e.g., cytotoxic T cells), T cell hybridomas, or other publicly available sources. In some embodiments, T cells can be obtained from cells separated in vivo. In some embodiments, high-affinity T cell clones can be isolated from patients, and TCR is isolated. In some embodiments, T cells can be cultured T cell hybridomas or clones. In some embodiments, TCR clones directed against a target antigen have been generated in transgenic mice engineered with human immune system genes (e.g., human leukocyte antigen system or HLA). See, for example, tumor antigens (see, for example, Parkhurst et al., 2009 and Cohen et al., 2005). In some embodiments, phage display is used to isolate TCRs directed against a target antigen (see, for example, Varela-Rohena et al., 2008 and Li, 2005). In some embodiments, a TCR or antigen binding portion thereof can be synthetically generated based on knowledge of the TCR sequence.

[0150] C. Antigen

[0151] Antigens targeted by genetically engineered antigen receptors include antigens expressed in the context of diseases, conditions or cell types targeted by adoptive cell therapy. Hyperplastic, neoplastic and malignant diseases and conditions are included in diseases and conditions, including cancer and tumors, including hematological cancers, immune system cancers, such as lymphomas, leukemias and / or myeloma, for example, B, T and myeloid leukemias, lymphomas and multiple myeloma. In some embodiments, antigens are selectively expressed or overexpressed on cells (e.g., tumors or pathogenic cells) of diseases or conditions compared to normal or non-targeted cells or tissues. In other embodiments, antigens are expressed on normal cells and / or expressed on engineered cells.

[0152] Any suitable antigen can be targeted in the present method. In some cases, the antigen may be associated with certain cancer cells but not with non-cancerous cells. Exemplary antigens include, but are not limited to, antigenic molecules from infectious agents, self / autoantigens, tumor / cancer-associated antigens, and tumor neoantigens (Linnemann et al., 2015). In particular aspects, antigens include NY-ESO, EGFRvIII, Muc-1, Her2, CA-125, WT-1, Mage-A3, Mage-A4, Mage-A10, TRAIL / DR4, and CEA. In particular aspects, antigens of two or more antigen receptors include, but are not limited to, CD19, EBNA, WT1, CD123, NY-ESO, EGFRvIII, MUC1, HER2, CA-125, WT1, Mage-A3, Mage-A4, Mage-A10, TRAIL / DR4, and / or CEA. The sequences of these antigens are known in the art, for example, in In the database: CD19 (accession number NG_007275.1), EBNA (accession number NG_002392.2), WT1 (accession number NG_009272.1), CD123 (accession number NC_000023.11), NY-ESO (accession number NC_000023.11), EGFRvIII (accession number NG_007726.3), MUC1 (accession number NG_029383.1), HER2 (accession number NG_007 503.1), CA-125 (Accession No. NG_055257.1), WT1 (Accession No. NG_009272.1), Mage-A3 (Accession No. NG_013244.1), Mage-A4 (Accession No. NG_013245.1), Mage-A10 (Accession No. NC_000023.11), TRAIL / DR4 (Accession No. NC_000003.12) and / or CEA (Accession No. NC_000019.10).

[0153] Tumor-associated antigens can be derived from, for example, prostate cancer, breast cancer, colorectal cancer, lung cancer, pancreatic cancer, kidney cancer, mesothelioma, ovarian cancer, liver cancer, brain cancer, bone cancer, stomach cancer, spleen cancer, testicular cancer, cervical cancer, anal cancer, gallbladder cancer, thyroid cancer, or melanoma cancer. Exemplary tumor-associated antigens or tumor cell-derived antigens include MAGE 1, 3, and MAGE 4 (or other MAGE antigens, such as those disclosed in International Patent Publication No. WO99 / 40188); PRAME; BAGE; RAGE, Lage (also known as NY ESO 1); SAGE; and HAGE or GAGE. These non-limiting examples of tumor antigens are expressed in a variety of tumor types (e.g., melanoma, lung cancer, sarcoma, and bladder cancer). See, for example, U.S. Pat. No. 6,544,518. Antigens associated with prostate cancer tumors include, for example, prostate specific membrane antigen (PSMA), prostate specific antigen (PSA), prostatic acid phosphate, NKX3.1, and six transmembrane epithelial antigen of the prostate (STEAP).

[0154] Other tumor-associated antigens include Plu-1, HASH-1, HasH-2, Cripto, and Criptin. In addition, tumor antigens can be self-peptide hormones, such as full-length gonadotropin-releasing hormone (GnRH), which is a short 10 amino acid long peptide that can be used to treat many cancers.

[0155] Tumor antigens include tumor antigens derived from cancers characterized by tumor-associated antigen expression, such as HER-2 / neu expression. Tumor-associated antigens of interest include lineage-specific tumor antigens, such as melanocyte-melanoma lineage antigens MART-1 / Melan-A, gp100, gp75, mda-7, tyrosinase, and tyrosinase-related proteins.

[0156] Exemplary cancer antigens include CD19, EBNA, CD123, HER2, CA-125, TRAIL / DR4, CD20, CD70, carcinoembryonic antigen, alpha-fetoprotein, CD56, AKT, Her3, epithelial tumor antigen, CD319 (CS1), ROR1, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, CD5, CD23, CD30, HERV-K, IL-11Rα, kappa chain, lambda chain, CSPG4, CD33, CD47, CLL-1, U5snRNP200, CD200, BAFF-R, BCMA, CD99, p53, mutant p53, Ras, mutant ras, c-Myc, cytoplasmic serine / threonine kinases (e.g., A-Raf, B-Raf and C-Raf,Cyclin-dependent kinases), MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MART-1, melanoma-associated antigen, BAGE, DAM-6, -10, GAGE-1, -2, -8, GAGE-3, -4, -5, -6, -7B, NA88-A, MC1R, mda-7, gp75, Gp100, PSA, PSM, tyrosinase, tyrosinase-related protein, TRP-1, TR P-2, ART-4, CAMEL, CEA, Cyp-B, hTERT, hTRT, iCE, MUC1, MUC2, phosphoinositide 3-kinase (PI3K), TRK receptor, PRAME, P15, RU1, RU2, SART-1, SART-3, Wilms' tumor antigen (WT1), AFP, -catenin / m, caspase-8 / m, CDK-4 / m, ELF2M, GnT-V, G250, HAGE, HSP70-2M, HS T-2, KIAA0205, MUM-1, MUM-2, MUM-3, myosin / m, RAGE, SART-2, TRP-2 / INT2, 707-AP, annexin II, CDC27 / m, TPI / mbcr-abl, BCR-ABL, interferon regulatory factor 4 (IRF4), ETV6 / AML, LDLR / FUT, Pml / RAR, tumor-associated calcium signal transducer 1 (TACSTD1), TACSTD2, receptor tyrosine kinases (e.g., epidermal growth factor receptor ( EGFR) (especially EGFRvIII), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR)), VEGFR2, cytoplasmic tyrosine kinases (such as src family, syk-ZAP70 family), integrin-linked kinase (ILK), signal transduction and transcription activator STAT3, STATS and STATE, hypoxia-inducible factors (such as HIF-1 and HIF-2), nuclear factor-κB (NF-B), Notch receptors (such as Notch1-4), NY ESO 1, c-Met, mammalian target of rapamycin (mTOR), WNT, extracellular signal-regulated kinase (ERK) and its regulatory subunits, PMSA, PR-3, MDM2, mesothelin, renal cell carcinoma-5T4, SM22-α, carbonic anhydrase I (CAI) and IX (CAIX) (also known as G250), STEAD, TEL / AML1, GD2, proteinase 3, hTERT, sarcoma translocation breakpoint, EphA2, ML-IAP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, androgen receptor,Cyclin B1, polysialic acid, MYCN, RhoC, GD3, fucosyl GM1, mesothelin, PSCA, sLe, PLAC1, GM3, BORIS, Tn, GLoboH, NY-BR-1, RGsS, SAGE, SART3, STn, PAX5, OY-TES1, sperm protein 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE1, B7H3, legumain, TIE2, Page4, MAD-CT-1, FAP, MAD-CT-2, fos-related antigen 1, CBX2, CLDN6, SPANX, TPTE, ACTL8, ANKRD30A, CDKN2A, MAD2L1, CTAG1B, SUNC1, and LRRN1.

[0157] Antigens may include antigenic epitope regions or antigenic epitope peptides derived from genes that are mutated in tumor cells or from genes that are transcribed at different levels in tumor cells compared to normal cells, such as telomerase, survivin, mesothelin, mutated ras, bcr / abl rearrangement, Her2 / neu, mutant or wild-type p53, cytochrome P450 1B1 and abnormally expressed intronic sequences, such as N-acetylglucosamine transferase-V; clonal rearrangements of immunoglobulin genes that produce unique idiotypes in myeloma and B-cell lymphoma; tumor antigens including epitope regions or epitope peptides derived from oncogenic viral processes, such as human papillomavirus proteins E6 and E7; Epstein bar virus protein LMP2; non-mutated oncofetal proteins with tumor-selective expression, such as carcinoembryonic antigen and alpha-fetoprotein.

[0158] In other embodiments, the antigen is obtained or derived from pathogenic microorganisms or opportunistic pathogenic microorganisms (also referred to herein as infectious microorganisms), such as viruses, fungi, parasites and bacteria. In certain embodiments, the antigen derived from such microorganisms includes full-length proteins.

[0159] Exemplary pathogenic organisms whose antigens are contemplated for use in the methods described herein include human immunodeficiency virus (HIV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza A, B, and C, vesicular stomatitis virus (VSV), polyomaviruses (e.g., BK virus and JC virus), adenoviruses, Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA), and Streptococcus species, including Streptococcus pneumoniae. As will be appreciated by those skilled in the art, proteins derived from these and other pathogenic microorganisms for use as antigens as described herein can be found in publications and public databases (e.g., and ) was identified.

[0160] Antigens derived from human immunodeficiency virus (HIV) include any of the following: HIV virion structural proteins (e.g., gp120, gp41, p17, p24), protease, reverse transcriptase or HIV proteins encoded by tat, rev, nef, vif, vpr and vpu.

[0161] Antigens derived from herpes simplex virus (e.g., HSV1 and HSV2) include, but are not limited to, proteins expressed from HSV late genes. The latter group of genes mainly encodes proteins that form virion particles. Such proteins include five proteins from (UL) that form the viral capsid: UL6, UL18, UL35, UL38 and major capsid proteins UL19, UL45 and UL27, each of which can be used as an antigen as described herein. Other exemplary HSV proteins that are expected to be used as antigens in this article include ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins. The HSV genome contains at least 74 genes, each of which encodes a protein that may be used as an antigen.

[0162] Antigens derived from cytomegalovirus (CMV) include CMV structural proteins, viral antigens expressed during the immediate early and early stages of viral replication, glycoproteins I and III, capsid proteins, coat proteins, lower matrix proteins pp65 (ppUL83), p52 (ppUL44), IE1 and 1E2 (UL123 and UL122), protein products from the gene cluster of UL128-UL150 (Rykman et al., 2006), envelope glycoprotein B (gB), gH, gN and pp150. As will be appreciated by those skilled in the art, CMV proteins useful as antigens described herein may be found, for example, in and The genes were identified in public databases (see, e.g., Bennekov et al., 2004; Loewendorf et al., 2010; Marschall et al., 2009).

[0163] Antigens derived from Epstein-Ban virus (EBV) contemplated for use in certain embodiments include EBV lytic proteins gp350 and gp110, EBV proteins produced during latent infection, including Epstein-Ban nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane protein (LMP)-1, LMP-2A and LMP-2B (see, e.g., Lockey et al., 2008).

[0164] Antigens derived from respiratory syncytial virus (RSV) intended for use herein include any one of the 11 proteins encoded by the RSV genome or their antigenic fragments: NS1, NS2, N (nucleocapsid protein), M (matrix protein) SH, G and F (viral coat proteins), M2 (second matrix protein), M2-1 (elongation factor), M2-2 (transcription regulator), RNA polymerase and phosphoprotein P.

[0165] Antigens derived from vesicular stomatitis virus (VSV) contemplated for use include any of the five major proteins encoded by the VSV genome and antigenic fragments thereof: large protein (L), glycoprotein (G), nucleoprotein (N), phosphoprotein (P) and matrix protein (M) (see, e.g., Rieder et al., 1999).

[0166] Antigens derived from influenza virus contemplated for use in certain embodiments include hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix proteins M1 and M2, NS1, NS2 (NEP), PA, PB1, PB1-F2, and PB2.

[0167] Exemplary viral antigens also include, but are not limited to, adenovirus polypeptides, alphavirus polypeptides, calicivirus polypeptides (e.g., calicivirus capsid antigens), coronavirus polypeptides, distemper virus polypeptides, Ebola virus polypeptides, enterovirus polypeptides, flavivirus polypeptides, hepatitis virus (AE) polypeptides (hepatitis B core or surface antigens, hepatitis C virus E1 or E2 glycoproteins, core or nonstructural proteins), herpesvirus polypeptides (including herpes simplex virus or varicella zoster virus glycoproteins), infectious peritonitis virus polypeptides, leukemia virus polypeptides, Marburg virus polypeptides, orthomyxovirus polypeptides, papillomavirus polypeptides, parainfluenza virus polypeptides (e.g., hemagglutinin and neuraminidase polypeptides), paramyxovirus polypeptides, parvovirus polypeptides, pestivirus polypeptides, picornavirus polypeptides (e.g., poliovirus capsid polypeptides), poxvirus polypeptides (e.g., vaccinia virus polypeptides), rabies virus polypeptides (e.g., rabies virus glycoprotein G), reovirus polypeptides, retrovirus polypeptides, and rotavirus polypeptides.

[0168] In certain embodiments, the antigen may be a bacterial antigen. In certain embodiments, the bacterial antigen of interest may be a secreted polypeptide. In certain other embodiments, the bacterial antigen includes an antigen having one or more portions of a polypeptide exposed on the outer cell surface of the bacterium.

[0169] Antigens derived from Staphylococcus species, including methicillin-resistant Staphylococcus aureus (MRSA), contemplated for use include virulence regulators, e.g., the Agr system, Sar and Sae, the Arl system, Sar homologs (Rot, MgrA, SarS, SarR, SarT, SarU, SarV, SarX, SarZ, and TcaR), the Srr system, and TRAP. Other staphylococcal proteins that may be used as antigens include the Clp protein, HtrA, MsrR, aconitase, CcpA, SvrA, Msa, CfvA, and CfvB (see, e.g., Staphylococcus: Molecular Genetics, 2008 Caister Academic Press, Ed. Jodi Lindsay). The genomes of two species of Staphylococcus aureus (N315 and Mu50) have been sequenced and are publicly available, for example, in PATRIC (PATRIC: The VBI PathoSystems Resource Integration Center, Snyder et al., 2007). As will be appreciated by those skilled in the art, the genomes of two species of Staphylococcus aureus (N315 and Mu50) may also be found in other public databases (e.g. and ) to identify Staphylococcal proteins for use as antigens.

[0170] Antigens from S. pneumoniae contemplated for use in certain embodiments described herein include pneumolysin, PspA, choline binding protein A (CbpA), NanA, NanB, SpnHL, PavA, LytA, Pht, and pili proteins (RrgA; RrgB; RrgC). Antigenic proteins of S. pneumoniae are also known in the art and can be used as antigens in some embodiments (see, e.g., Zysk et al., 2000). The complete genome sequence of a virulent strain of S. pneumoniae has been sequenced, and as will be appreciated by those skilled in the art, S. pneumoniae proteins for use herein may also be found in other public databases such as and According to the present disclosure, proteins of particular interest for antigens include virulence factors and proteins predicted to be exposed on the surface of pneumococci (see, e.g., Frolet et al., 2010).

[0171] Examples of bacterial antigens that can be used as antigens include, but are not limited to, Actinomyces polypeptides, Bacillus polypeptides, Bacteroides polypeptides, Bordetella polypeptides, Bartonella polypeptides, Borrelia polypeptides (e.g., B. burgdorferi OspA), Brucella polypeptides, Campylobacter polypeptides, Capnocytophaga polypeptides, Chlamydia polypeptides, amydia polypeptides, Corynebacterium polypeptides, Coxiella polypeptides, Dermatophilus polypeptides, Enterococcus polypeptides, Ehrlichia polypeptides, Escherichia polypeptides, Francisella polypeptides, Fusobacterium polypeptides, Haemobartonella polypeptides, Haemophilus polypeptides (e.g., Haemophilus influenzae type b) Membrane protein), Helicobacter polypeptide, Klebsiella polypeptide, L-bacterial polypeptide, Leptospira polypeptide, Listeria polypeptide, Mycobacteria polypeptide, Mycoplasma polypeptide, Neisseria polypeptide, Neorickettsia polypeptide, Nocardia polypeptide, Pasteurella polypeptide, Peptococcus polypeptide, Peptostreptococcus polypeptide Peptostreptococcus polypeptides, Pneumococcus polypeptides (i.e., S. pneumoniae polypeptides), Proteus polypeptides, Pseudomonas polypeptides, Rickettsia polypeptides, Rochalimaea polypeptides, Salmonella polypeptides, Shigella polypeptides, Staphylococcus polypeptides, Group A Streptococcus polypeptides (e.g., S. pyogenes M protein), Group B Streptococcus (S. agalactiae polypeptides),agalactiae) polypeptides, Treponema polypeptides, and Yersinia polypeptides (e.g., Y pestis F1 and V antigens).

[0172] Examples of fungal antigens include, but are not limited to, Absidia polypeptides, Acremonium polypeptides, Alternaria polypeptides, Aspergillus polypeptides, Basidiobolus polypeptides, Bipolaris polypeptides, Blastomyces polypeptides, Candida polypeptides, Coccidioides polypeptides, Conidiobolus polypeptides, Cryptococcus polypeptides, Curvalaria polypeptides, Epidermophyton polypeptides, Exophiala polypeptides, Geotrichum polypeptides, Histoplasma polypeptides, Madurella polypeptides, Malassezia polypeptides, Microsporum polypeptides, Microplexus polypeptides, Moniliella polypeptide, Mortierella polypeptide, Mucor polypeptide, Paecilomyces polypeptide, Penicillium polypeptide, Philalemonium polypeptide, Phialophora polypeptide, Prototheca polypeptide, Pseudallescheria polypeptide, Pseudomicr The polypeptides include, but are not limited to, polypeptides of the genus Odochium, polypeptides of the genus Pythium, polypeptides of the genus Rhinosporidium, polypeptides of the genus Rhizopus, polypeptides of the genus Scolecobasidium, polypeptides of the genus Sporothrix, polypeptides of the genus Stemphylium, polypeptides of the genus Trichophyton, polypeptides of the genus Trichosporon, and polypeptides of the genus Xylohypha.

[0173] Examples of protozoan parasite antigens include, but are not limited to, Babesia polypeptides, Balantidium polypeptides, Besnoitia polypeptides, Cryptosporidium polypeptides, Eimeria polypeptides, Encephalitozoon polypeptides, Entamoeba polypeptides, Giardia polypeptides, Hammondia polypeptides, Hepatozoon polypeptides, Isospora polypeptides, Leishmania polypeptides, Microsporidia polypeptides, Neospora polypeptides, Nosema polypeptides, Pentatrichomonas polypeptides, Plasmodium polypeptides.Examples of helminth parasite antigens include, but are not limited to, Acanthocheilonema polypeptides, Aelurostrongylus polypeptides, Ancylostoma polypeptides, Angiostrongylus polypeptides, Ascaris polypeptides, Brugia polypeptides, Bunostomum polypeptides, Capillaria polypeptides, Chabertia polypeptides, Cooperia polypeptides, Crenosoma polypeptides, Dictyocaulus polypeptides, peptides, Dioctophyme polypeptides, Dipetalonema polypeptides, Diphyllobothrium polypeptides, Diplydium polypeptides, Dirofilaria polypeptides, Dracunculus polypeptides, Enterobius polypeptides, Filaroides polypeptides, Haemonchus polypeptides, Lagochilascaris polypeptides, Loa polypeptides, Mansonella polypeptides, Muellerius polypeptides, Nanofluke polypeptides, phyetus polypeptide, Necator polypeptide, Nematodirus polypeptide, Oesophagostomum polypeptide, Onchocerca polypeptide, Opisthorchis polypeptide, Ostertagia polypeptide, Parafilaria polypeptide, Paragonimus polypeptide, Parascaris polypeptide, Physaloptera polypeptide, Protostrongylus polypeptide, Setaria polypeptide, Spirocerca polypeptides, Spirometra polypeptides, Stephanofilaria polypeptides, Strongyloides polypeptides, Strongylus polypeptides, Thelazia polypeptides, Toxascaris polypeptides, Toxocara polypeptides, Trichinella polypeptides, Trichostrongylus polypeptides, Trichuris polypeptides, Uncinaria polypeptides and Wuchereria polypeptides.falciparum circumsporozoite (PfCSP), sporozoite surface protein 2 (PfSSP2), carboxyl terminus of liver state antigen 1 (PfLSA1 c-term) and export protein 1 (PfExp-1), Pneumocystis polypeptides, Sarcocystis polypeptides, Schistosoma polypeptides, Theileria polypeptides, Toxoplasma polypeptides and Trypanosoma polypeptides.

[0174] Examples of ectoparasite antigens include, but are not limited to, polypeptides (including antigens as well as allergens) from: fleas; ticks, including hard ticks and soft ticks; flies, such as midges, mosquitoes, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, stable flies, myiasis-causing flies and biting mosquitoes; ants; spiders, lice; mites; and true bugs, such as bed bugs and assassin bugs.

[0175] D.Suicide gene

[0176] In some cases, any cell of the present disclosure is modified to produce one or more agents other than heterologous cytokines, engineered receptors, etc. In a specific embodiment, cells such as MSCs are engineered to carry one or more suicide genes, and the term "suicide gene" as used herein is defined as a gene that achieves a transition of a gene product to a compound that kills its host cell after administration of a prodrug. In some cases, when an individual receiving MSC treatment and / or who has received MSC treatment shows one or more symptoms of one or more adverse events (e.g., cytokine release syndrome, neurotoxicity, anaphylaxis / allergic reaction and / or on-target / off-tumor toxicity (e.g.) or is considered to be at risk of having said one or more symptoms, including urgently), MSC therapy can be subjected to the use of one or more suicide genes of any type. The use of suicide genes can be part of a treatment plan, or may be used only when it is considered necessary to use them. In some cases, since treatment is no longer needed, cell therapy is terminated by using one or more agents targeting suicide genes or their gene products.

[0177] Examples of suicide genes include engineered non-secretable (including membrane-bound) tumor necrosis factor (TNF)-α mutant polypeptides (see PCT / US19 / 62009, which is incorporated herein by reference in its entirety), and they can be targeted by delivering antibodies that bind to TNF-α mutants. Examples of suicide gene / prodrug combinations that can be used are herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir, acyclovir or FIAU; oxidoreductase and cycloheximide; cytosine deaminase and 5-fluorocytosine; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine arabinoside. Escherichia coli purine nucleoside phosphorylase, a so-called suicide gene, can be used, which converts the prodrug 6-methylpurine deoxyribonucleoside into the toxic purine 6-methylpurine. Other suicide genes include, for example, CD20, CD52, inducible caspase 9, purine nucleoside phosphorylase (PNP), cytochrome p450 enzymes (CYP), carboxypeptidase (CP), carboxylesterase (CE), nitroreductase (NTR), guanine ribosyltransferase (XGRTP), glycosidase, methionine-α, γ-lyase (MET), and thymidine phosphorylase (TP).

[0178] E. Delivery Method

[0179] In some embodiments, one or more compositions, including antigen receptors and / or cytokines, are delivered to MSCs, such as nucleic acids or proteins. Those skilled in the art will be fully equipped to construct vectors for expression of antigen receptors of the present disclosure by standard recombinant techniques (see, e.g., Sambrook et al., 2001 and Ausubel et al., 1996, both incorporated herein by reference). Vectors include, but are not limited to, plasmids, cosmids, viruses (bacteriophages, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs), such as retroviral vectors (e.g., derived from Moloney murine leukemia virus vector (MoMLV), MSCV, SFFV, MPSV, SNV, etc.), lentiviral vectors (e.g., derived from HIV-1, HIV-2, SIV, BIV, FIV, etc.), adenovirus (Ad) vectors, including replication-competent, replication-deficient, and viral gene-free forms thereof, adenovirus-associated virus (AAV) vectors, simian virus 40 (SV-40) vectors, bovine papillomavirus vectors, Epstein-Barr virus vectors, herpesvirus vectors, vacciniavirus vectors, Harvey murine sarcoma virus vectors, mouse mammary tumor virus vectors, Rous sarcoma virus vectors, parvovirus vectors, poliovirus vectors, vesicular stomatitis virus vectors, maraba virus vectors, and group B adenovirus enadenotucirev vectors.

[0180] In a specific embodiment, the vector is a polycistronic vector, such as described in PCT / US19 / 62014, which is incorporated herein by reference in its entirety. In this case, a single vector can encode a CAR or TCR (and the expression construct can be configured in a modular format to allow for the interchange of parts of the CAR or TCR), a suicide gene, and one or more cytokines.

[0181] 1. Viral vectors

[0182] In some aspects of the present disclosure, a viral vector encoding an antigen receptor can be provided. In the production of recombinant viral vectors, non-essential genes are usually replaced with genes or coding sequences of heterologous (or non-natural) proteins. A viral vector is an expression construct that utilizes viral sequences to introduce nucleic acids and possibly proteins into cells. The ability of certain viruses to infect cells or enter cells and integrate into the host cell genome and stably and effectively express viral genes through receptor-mediated endocytosis makes it an attractive candidate for transferring foreign nucleic acids into cells (e.g., mammalian cells). Non-limiting examples of viral vectors that can be used to deliver nucleic acids in some aspects of the present invention are described below.

[0183] Lentiviruses are complex retroviruses that, in addition to the common retroviral genes gag, pol and env, contain other genes with regulatory or structural functions. Lentivirus vectors are well known in the art (see, e.g., U.S. Patents 6,013,516 and 5,994,136).

[0184] Recombinant lentiviral vectors are capable of infecting non-dividing cells and can be used for in vivo and ex vivo gene transfer and expression of nucleic acid sequences. For example, recombinant lentiviruses capable of infecting non-dividing cells are described in U.S. Pat. No. 5,994,136 (incorporated herein by reference), wherein suitable host cells are transfected with two or more vectors carrying packaging functions (i.e., gag, pol and env as well as rev and tat).

[0185] a. Regulatory elements

[0186] The expression cassette included in the vector useful in the present disclosure particularly comprises (along the 5' to 3' direction) a eukaryotic transcription promoter operably connected to a protein coding sequence, a splicing signal comprising an intervening sequence and a transcription termination / polyadenylation sequence. The promoter and enhancer controlling the transcription of protein coding genes in eukaryotic cells are composed of a variety of genetic elements. The cellular machinery is able to collect and integrate the regulatory information conveyed by each element, thereby allowing different genes to evolve unique, usually complex transcriptional regulatory patterns. The promoter used in the context of the present disclosure includes constitutive, inducible and tissue-specific promoters.

[0187] b. Promoter / enhancer

[0188] The expression construct provided herein comprises a promoter that drives antigen receptor expression. The promoter generally comprises a sequence for locating the start site of RNA synthesis. For this, the most well-known example is the TATA box, but in some promoters lacking the TATA box (for example, the promoter of the mammalian terminal deoxynucleotidyl transferase gene and the promoter of the SV40 late gene), the discrete elements that cover the start site themselves help fix the start position. Other promoter elements regulate the frequency of transcription initiation. Usually, these promoters are located in the region of 30110bp upstream of the start site, although it has been shown that many promoters also contain functional elements downstream of the start site. In order to make the coding sequence "under the control" of the promoter, the 5' end of the transcription start site of the transcription reading frame is positioned at the "downstream" (i.e. 3') of the selected promoter. The promoter of "upstream" stimulates the transcription of DNA and promotes the expression of the RNA encoded.

[0189] The spacing between promoter elements is often flexible, so that promoter function is retained when the elements are inverted or moved relative to each other. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that the individual elements can act either synergistically or independently to activate transcription. A promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence.

[0190] The promoter may be a promoter naturally associated with a nucleic acid sequence, such as can be obtained by isolating a 5' non-coding sequence located upstream of a coding segment and / or an exon. Such a promoter may be referred to as "endogenous". Similarly, an enhancer may be an enhancer naturally associated with a nucleic acid sequence, located downstream or upstream of the sequence. Alternatively, certain advantages may be obtained by placing the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not usually associated with a nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer also refers to an enhancer that is not usually associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes, as well as promoters or enhancers isolated from any other virus, prokaryotic or eukaryotic cells, and promoters or enhancers that are not "naturally present", i.e., different elements comprising different transcriptional regulatory regions, and / or mutations that alter expression. For example, the promoters most commonly used for recombinant DNA construction include β-lactamase (penicillinase), lactose, and tryptophan (trp-) promoter systems. In addition to synthetically generating promoter and enhancer nucleic acid sequences, recombinant cloning and / or nucleic acid amplification techniques (including PCR) can also be used in conjunction with the compositions disclosed herein. TM) to generate the sequence. In addition, it is contemplated that control sequences that direct transcription and / or expression of the sequence within non-nuclear organelles (e.g., mitochondria, chloroplasts, etc.) may also be employed.

[0191] Naturally, it is important to use promoters and / or enhancers that effectively direct the expression of the DNA segment in the organelle, cell type, tissue, organ or organism selected for expression. The use of promoters, enhancers and cell type combinations for protein expression is generally known to those skilled in the art of molecular biology (see, e.g., Sambrook et al., 1989, incorporated herein by reference). The promoter used can be constitutive, tissue-specific, inducible and / or can be used to direct high-level expression of the introduced DNA segment under appropriate conditions, for example, in large-scale production of recombinant proteins and / or peptides. The promoter can be heterologous or endogenous.

[0192] In addition, any promoter / enhancer combination (e.g., according to the Eukaryotic Promoter Database EPDB, accessed via the website epd.isb-sib.ch / ) can also be used to drive expression. The use of T3, T7 or SP6 cytoplasmic expression systems is another possible embodiment. Eukaryotic cells can support cytoplasmic transcription of certain bacterial promoters if the appropriate bacterial polymerase is provided (either as part of the delivery complex or as an additional gene expression construct).

[0193] Non-limiting examples of promoters include early or late viral promoters, such as SV40 early or late promoters, cytomegalovirus (CMV) immediate early promoter, Rous sarcoma virus (RSV) early promoter; eukaryotic promoters, such as β-actin promoter, GADPH promoter, metallothionein promoter; and tandem response element promoters, such as cyclic AMP response element promoter (cre), serum response element promoter (sre), phorbol ester promoter (TPA) and minimal TATA box near the response element promoter (tre). Human growth hormone promoter sequence (e.g., human growth hormone minimal promoter described in Genbank accession number X05244, nucleotides 283-341) or mouse mammary tumor promoter (available from ATCC catalog number ATCC 45007) can also be used. In certain embodiments, the promoter is a CMV IE, dectin-1, dectin-2, human CD11c, F4 / 80, SM22, RSV, SV40, Ad MLP, β-actin, MHC class I, or MHC class II promoter, but any other promoter that can be used to drive expression of a therapeutic gene is suitable for the practice of the present disclosure.

[0194] In certain aspects, the methods of the present disclosure also relate to enhancer sequences, i.e., nucleic acid sequences that increase the activity of a promoter and have the potential to act in cis regardless of its orientation, even at relatively long distances (up to several kilobases from the target promoter). However, enhancer function is not necessarily limited to such long distances, as they can also act in close proximity to a given promoter.

[0195] c. Initiation signal and linked expression

[0196] Specific start signals can also be used in the expression constructs provided in the present disclosure for efficient translation of the coding sequence. These signals include the ATG start codon or adjacent sequences. It may be necessary to provide exogenous translation control signals, including the ATG start codon. One of ordinary skill in the art will be able to easily determine this and provide the necessary signals. It is well known that the start codon must be "in frame" with the reading frame of the desired coding sequence to ensure translation of the entire inserted sequence. Exogenous translation control signals and start codons can be natural or synthetic. Expression efficiency can be improved by including appropriate transcription enhancer elements.

[0197] In certain embodiments, internal ribosome entry site (IRES) elements are used to produce polygene or polycistronic messengers. The IRES element can bypass the ribosome scanning model of 5' methylated Cap-dependent translation and start translation at the internal site. The IRES elements from two members of the picornavirus family (poliomyelitis and encephalomyocarditis) and the IRES from mammalian messengers have been described. The IRES element can be connected to a heterologous open reading frame. Multiple open reading frames can be transcribed together, each separated by an IRES, thereby producing a polycistronic messenger. By means of an IRES element, ribosomes can approach each open reading frame to effectively translate. Using a single promoter / enhancer to transcribe a single messenger can effectively express multiple genes.

[0198] In addition, certain 2A sequence elements can be used to generate linked expression or co-expression of genes in constructs provided by the present disclosure. For example, by connecting open reading frames to form a single cistron, a cleavage sequence can be used to co-express genes. An exemplary cleavage sequence is F2A (foot-and-mouth disease virus 2A) or a "2A-like" sequence (e.g., Thosea asigna virus 2A; T2A).

[0199] d. Origin of replication

[0200] In order to propagate the vector in the host cell, it may contain one or more replication origin sites (commonly referred to as "ori"), for example, a nucleic acid sequence corresponding to oriP of EBV as described above or a genetically engineered oriP having similar or enhanced functions in programming, the replication origin site being a specific nucleic acid sequence at which replication is initiated. Alternatively, the replication origins of other extrachromosomal replicating viruses as described above or autonomous replication sequences (ARS) may be used.

[0201] e. Selectable and screenable markers

[0202] In some embodiments, cells containing constructs of the present disclosure can be identified in vitro or in vivo by including a marker in the expression vector. Such a marker will confer recognizable changes to the cell, thereby allowing easy identification of cells containing the expression vector. Generally, a selective marker is a marker that confers a property that allows selection. A positive selection marker is a marker in which the presence of the marker allows its selection, while a negative selection marker is a marker in which its presence prevents its selection. An example of a positive selection marker is a drug resistance marker.

[0203] The inclusion of conventional drug selection markers helps to clone and identify transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selection markers. In addition to conferring markers that allow the phenotype of transformants to be distinguished based on conditional implementation, other types of markers are also contemplated, including screenable markers, such as GFP based on colorimetric analysis. Alternatively, screenable enzymes can be used as negative selection markers, such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT). Those skilled in the art will also know how to use immunological markers, possibly in conjunction with FACS analysis. The marker used is believed to be unimportant, as long as it can be expressed simultaneously with the nucleic acid encoding the gene product. Other examples of selectivity and screenable markers are well known to those skilled in the art.

[0204] 2. Other methods of nucleic acid delivery

[0205] In addition to viral delivery of nucleic acids encoding antigen receptors, the following are other methods of delivering recombinant genes to a given host cell and are therefore contemplated in the present disclosure.

[0206] As described herein or as known to those of ordinary skill in the art, nucleic acids (e.g., DNA or RNA) are introduced into immune cells of the present disclosure using any suitable method for nucleic acid delivery to transform cells. Such methods include, but are not limited to, direct delivery of DNA, such as by ex vivo transfection, by injection (including microinjection); by electroporation; by calcium phosphate precipitation; by using DEAE-dextran followed by polyethylene glycol; by direct sonic loading; by liposome-mediated transfection and receptor-mediated transfection; by microparticle bombardment; by stirring with silicon carbide fibers; by Agrobacterium-mediated transformation; by drying / inhibition-mediated DNA uptake, and any combination of these methods. By applying techniques such as these, organelles, cells, tissues, or organisms can be stably or transiently transformed.

[0207] V. Gene Editing and CRISPR

[0208] The MSC production methods of the present disclosure include gene editing of MSCs. In some cases, gene editing occurs in MSCs that express one or more heterologous antigen receptors, while in other cases, gene editing occurs in MSCs that do not express heterologous antigen receptors. In certain embodiments, gene-edited MSCs may or may not be expanded MSCs.

[0209] In certain cases, one or more endogenous genes of MSCs are modified, such as expression is disrupted, wherein expression is partially or completely reduced. In certain cases, one or more genes are knocked down or knocked out using the methods of the present disclosure. In certain cases, multiple genes are knocked down or knocked out in the same steps as the methods of the present disclosure. The genes edited in MSCs can be of any kind, but in certain embodiments, the genes are genes whose gene products inhibit the activity and / or proliferation of MSCs. In certain cases, the genes edited in MSCs allow MSCs to work more effectively in the tumor microenvironment. In certain instances, the gene is one or more of: NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, TDAG8, CD5, CD7, SLAMF7, CD38, LAG3, TCR, β2-microglobulin, HLA, CD73, and CD39. In certain embodiments, the TGFBR2 gene is knocked out or knocked down in MSCs.

[0210] In some embodiments, gene editing is performed using one or more DNA binding nucleic acids, for example, by RNA-guided endonucleases (RGENs). For example, regularly spaced clustered short palindromic repeats (CRISPR) and CRISPR-related (Cas) proteins can be used to change. Generally, "CRISPR system" generally refers to transcripts and other elements related to the expression of CRISPR-related ("Cas") genes or the activity of guiding CRISPR-related ("Cas") genes, including sequences encoding Cas genes, tracr (trans-activating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr pairing sequences (partial direct repeats processed by "direct repeats" and tracrRNA in the context of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems) and / or other sequences and transcripts from CRISPR loci.

[0211] CRISPR / Cas nuclease or CRISPR / Cas nuclease system can include a non-coding RNA molecule (guide) RNA (which sequence-specifically binds to DNA) and a Cas protein (e.g., Cas9) having nuclease function (e.g., two nuclease domains). One or more elements of the CRISPR system can be derived from a type I, type II, or type III CRISPR system, such as from a specific organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.

[0212] In some aspects, Cas nuclease and gRNA (including fusion of crRNA and fixed tracrRNA specific to target sequence) are introduced into cells. Typically, complementary base pairing is used to target Cas nuclease to target site, such as gene, at the target site at the 5' end of gRNA. The target site can be selected based on the 5' position (e.g., generally NGG or NAG) of its adjacent protospacer sequence adjacent to the motif (PAM) sequence. In this regard, gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11 or 10 nucleotides of the guide RNA to correspond to the target DNA sequence. Typically, the CRISPR system is characterized by promoting the elements of the CRISPR complex formation at the target sequence site. Typically, "target sequence" generally refers to a sequence designed to have complementarity with the guide sequence, wherein the hybridization between the target sequence and the guide sequence promotes the formation of the CRISPR complex. If there is enough complementarity to cause hybridization and promote the formation of the CRISPR complex, it is not necessarily necessary to be fully complementary.

[0213] The CRISPR system can induce double-strand breaks (DSBs) at the target site, subsequently causing damage or changes as discussed herein. In other embodiments, Cas9 variants considered to be "nickases" are used to nick single strands at the target site. Paired nickases can be used, for example, to improve specificity, each of which is guided by different gRNA targeting sequences, so that when the nicks are introduced at the same time, 5' overhangs are introduced. In other embodiments, catalytically inactive Cas9 is fused to a heterologous effector domain, such as a transcriptional repressor or activator, to affect gene expression.

[0214] The target sequence can include any polynucleotide, such as a DNA or RNA polynucleotide. The target sequence can be located in the nucleus or cytoplasm of the cell, such as in an organelle of the cell. Typically, a sequence or template that can be used to reorganize a target locus comprising a target sequence is referred to as an "editing template" or "editing polynucleotide" or "editing sequence". In some aspects, an exogenous template polynucleotide can be referred to as an editing template. In some aspects, recombination is homologous recombination.

[0215] Typically, in the case of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs of the target sequence). The tracr sequence (which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g., about or greater than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence) can also form part of a CRISPR complex, e.g., by hybridizing along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence operably linked to a guide sequence. The tracr sequence has sufficient complementarity to the tracr mate sequence to hybridize and participate in the formation of a CRISPR complex, e.g., at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% sequence complementarity along the length of the tracr mate sequence when optimally matched.

[0216] One or more vectors driving the expression of one or more elements of the CRISPR system can be introduced into cells so that the expression of the elements of the CRISPR system guides the formation of a CRISPR complex at one or more target sites. Components can also be delivered to cells as proteins and / or RNA. For example, Cas enzymes, guide sequences connected to tracr-pairing sequences, and tracr sequences can each be operably connected to a separate regulatory element on a separate vector. Alternatively, two or more elements expressed from the same or different regulatory elements can be combined in a single vector, and one or more additional vectors provide any components of the CRISPR system not included in the first vector. The vector may include one or more insertion sites, such as restriction endonuclease recognition sequences (also referred to as "cloning sites"). In some embodiments, one or more insertion sites are located upstream and / or downstream of one or more sequence elements of one or more vectors. When using multiple different guide sequences, a single expression construct can be used to target CRISPR activity to multiple different corresponding target sequences in the cell.

[0217] The vector may comprise a regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme (e.g., a Cas protein). Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified forms thereof. These enzymes are known; for example, the amino acid sequence of the Streptococcus pyogenes Cas9 protein can be found in the SwissProt database under accession number Q99ZW2.

[0218] The CRISPR enzyme can be Cas9 (e.g., from Streptococcus pyogenes or Streptococcus pneumoniae). The endonuclease can be CpF1 instead of Cas9 protein. The CRISPR enzyme can guide the cutting of one or two chains at the target sequence position, for example, within the target sequence and / or within the complementary sequence of the target sequence. The vector can encode a CRISPR enzyme that is mutated relative to the corresponding wild-type enzyme, so that the mutated CRISPR enzyme lacks the ability to cut one or two chains of the target polynucleotide containing the target sequence. For example, the aspartic acid to alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from Streptococcus pyogenes converts Cas9 from a nuclease that cuts two chains to a nickase (cutting a single strand). In some embodiments, the Cas9 nickase can be used in combination with one or more guide sequences, such as two guide sequences (which target the sense and antisense strands of the DNA target, respectively). This combination allows both chains to be nicked and used to induce NHEJ or HDR.

[0219] In some embodiments, the enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in a specific cell (e.g., a eukaryotic cell). The eukaryotic cell can be a eukaryotic cell of a specific organism (e.g., a mammal, including but not limited to humans, mice, rats, rabbits, dogs, or non-human primates) or a eukaryotic cell derived from the specific organism. In general, codon optimization refers to the process of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of a native sequence with a codon that is more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. Various species exhibit specific biases for certain codons of specific amino acids. Codon bias (differences in codon usage between organisms) is generally associated with the translation efficiency of messenger RNA (mRNA), which in turn is believed to depend on (among other things) the nature of the codons translated and the availability of specific transfer RNA (tRNA) molecules. The advantage of the selected tRNA in the cell generally reflects the most commonly used codons in peptide synthesis. Therefore, genes can be customized for optimal gene expression in a given organism based on codon optimization.

[0220] In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity to a target polynucleotide sequence to hybridize to the target sequence and guide sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97%, 99% or more when optimally aligned using a suitable alignment algorithm.

[0221] Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of algorithms include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler transform (e.g., the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).

[0222] The CRISPR enzyme can be part of a fusion protein comprising one or more heterologous protein domains. The CRISPR enzyme fusion protein may comprise any other protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that can be fused to the CRISPR enzyme include, but are not limited to, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcriptional activation activity, transcriptional repression activity, transcriptional release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-5-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and autofluorescent proteins including blue fluorescent protein (BFP). The CRISPR enzyme can be fused to a gene sequence encoding a protein or protein fragment that binds to a DNA molecule or binds to other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusion, GAL4A DNA binding domain fusion and herpes simplex virus (HSV) BP16 protein fusion. Other domains that can form part of a fusion protein comprising a CRISPR enzyme are described in US 20110059502, which is incorporated herein by reference.

[0223] VI. Treatment Methods

[0224] In some embodiments, the MSCs produced by the methods of the present disclosure are used in methods of treating an individual in need thereof. As an example, embodiments of the present disclosure include methods of treating cancer, any type of infection, and / or any immune disorder in an individual. An individual may use the methods of the present disclosure as an initial treatment or after (or with) another treatment. Immunotherapeutic methods may be customized to the needs of an individual with cancer based on the type and / or stage of the cancer, and in at least some cases, immunotherapy may be modified during the course of treatment of an individual.

[0225] In specific cases, examples of treatment methods are as follows: 1) adoptive cell therapy using generated MSCs (expanded ex vivo or expressing CARs or TCRs) to treat cancer patients with any type of hematological malignancies; 2) adoptive cell therapy using generated MSCs (expanded ex vivo or expressing CARs or TCRs) to treat cancer patients with any type of solid cancer; (3) adoptive cell therapy using generated MSCs (expanded ex vivo or expressing CARs or TCRs) to treat patients with infectious or immune diseases.

[0226] In some embodiments, the disclosure provides a method for immunotherapy, the method comprising administering an effective amount of MSC produced by the method of the disclosure. In one embodiment, a medical disease or condition is treated by the transfer of a MSC colony produced by the method described herein and causing an immune response. In certain embodiments of the disclosure, cancer or infection is treated by transferring a MSC colony produced by the method of the disclosure and causing an immune response. Provided herein is a method for treating or delaying cancer progression in an individual, comprising administering an effective amount of antigen-specific cell therapy to the individual. The method of the present invention can be used to treat immune disorders, solid cancers, hematological cancers and / or viral infections.

[0227] The tumors that the treatment methods of the present invention can be used for include any malignant tumor cell type, such as those found in solid tumors or hematologic tumors. Exemplary solid tumors may include, but are not limited to, tumors of organs selected from pancreas, colon, cecum, stomach, brain, head, neck, ovary, kidney, larynx, sarcoma, lung, bladder, melanoma, prostate and breast. Exemplary hematologic tumors include bone marrow, T or B cell malignancies, leukemia, lymphoma, blastoma, myeloma, etc. Other examples of cancers that can be treated using the methods provided herein include, but are not limited to, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and lung squamous cell carcinoma), peritoneal cancer, gastric cancer or stomach cancer (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, various types of head and neck cancer, and melanoma.

[0228] The cancer may specifically be of the following histological types, but is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant cell and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatricoma carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyps; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; bronchoalveolar adenocarcinoma; papillary adenocarcinoma; chromophobe cell carcinoma; oncocytic carcinoma; oncocytic adenocarcinoma; basophilic granulocytic carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; sclerosing without encapsulation carcinoma; adrenocortical carcinoma; endometrioid carcinoma; carcinoma of skin appendages; apocrine carcinoma; sebaceous carcinoma; cervical carcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease, breast; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma with squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; theca cell tumor, malignant; granulosa cell tumor, malignant; male cell tumor, malignant; sertoli cell carcinoma; Leydig cell tumor, malignant; lipid cell tumor, malignant; paraganglioma, malignant; extramammary paraganglioma, malignant; pheochromocytoma; glomus sarcoma; malignant melanoma; non-melanoma melanoma; superficial spreading melanoma; lentigo malignant melanoma; acral lentigo melanoma; nodular melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrohistiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumor, malignant; Muller mixed tumor; Wilms tumor; hepatoblastoma carcinoma; carcinosarcoma; stromal tumor, malignant; Brenner tumor, malignant; phyllodes tumor, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; ovarian goiter, malignant; choriocarcinoma; mesonephroblastoma, malignant; angiosarcoma ; Hemangioendothelioma, malignant; Kaposi's sarcoma; Hemangiopericytoma, malignant; Lymphangiosarcoma; Osteosarcoma; Juxtacortical osteosarcoma; Chondrosarcoma; Chondroblastoma, malignant; Mesenchymal chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Odontogenic tumor, malignant; Ameloblastic odontosarcoma; Ameloblastoma, malignant; Ameloblastic fibrosarcoma; Pinealoma, malignant; Chordoma; Glioma, malignant; Ependymoma; Astrocytoma; Protoplasmic astrocytoma; Fibrous astrocytoma; Astroblastoma; Glioblastoma; Oligodendroglioma; Oligodendroglioma; Primitive neuroectodermal; Cerebellar sarcoma; Ganglioneuroblastoma; Neuroblastoma; Retinoblastoma; Olfactory neurogenic tumor; Meningioma, malignant;Neurofibrosarcoma; Schwannoma, malignant; Granular cell tumor, malignant; Lymphoma, malignant; Hodgkin's disease; Hodgkin's; Paragranuloma; Lymphoma, malignant, small lymphocytic; Lymphoma, malignant, large cell, diffuse; Lymphoma, malignant, follicular; Mycosis fungoides; Other specified non-Hodgkin's lymphoma; B-cell lymphoma; Low-grade / follicular non-Hodgkin's lymphoma (NHL); Small lymphocytic (SL) NHL; Intermediate / follicular NHL; Intermediate-grade diffuse NHL; High-grade immunoblastic NHL; High-grade lymphoblastic NHL; High-grade small non-lytic cell NHL; Bulky disease)NHL; mantle cell lymphoma; AIDS-related lymphoma; Waldenstrom macroglobulinemia; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; hairy cell leukemia; chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); and chronic myeloblastic leukemia. ;

[0229] Particular embodiments relate to methods of treating leukemia. Leukemia is a cancer of the blood or bone marrow characterized by abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes). It is part of a broad group of diseases known as hematologic neoplasms. Leukemia is a broad term covering a range of diseases. Leukemia is clinically and pathologically divided into acute and chronic forms.

[0230] In certain embodiments of the present disclosure, MSCs are delivered to individuals in need, such as individuals with cancer or infection. These cells then enhance the individual's immune system to attack the corresponding cancer or pathogenic cells. In some cases, one or more doses of MSCs are provided to an individual. In the case of providing two or more doses of MSCs to an individual, the duration between administrations should be sufficient to allow time for reproduction in the individual, and in specific embodiments, the duration between doses is 1, 2, 3, 4, 5, 6, 7 days or more.

[0231] Certain embodiments of the present disclosure provide methods for treating or preventing immune-mediated disorders. In one embodiment, the subject suffers from an autoimmune disease. Non-limiting examples of autoimmune diseases include: alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, adrenal autoimmune disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac dermatitis, and eczema. spate-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, idiopathic mixed cryoglobulinemia, fibromyalgia-fibromyositis; glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, nephrotic syndrome (e.g., mild change disease, focal glomerulosclerosis, or membranous nephropathy), pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Rett syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiffness syndrome, systemic lupus erythematosus, lupus erythematosus, ulcerative colitis, uveitis, vasculitis (e.g., polyarteritis nodosa, Takayasu's arteritis, temporal arteritis / giant cell arteritis, or dermatitis herpetiformis vasculitis), vitiligo, and Wegener's granulomatosis. Thus, some examples of autoimmune diseases that can be treated using the methods disclosed herein include, but are not limited to, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, Crohn's disease, ulcerative colitis, myasthenia gravis, glomerulonephritis, ankylosing spondylitis, vasculitis, or psoriasis. The subject may also suffer from an allergic condition, such as asthma.

[0232] In another embodiment, the subject is a recipient of a transplanted organ or stem cell, and the immune cells are used to prevent and / or treat rejection. In a specific embodiment, the subject suffers from graft-versus-host disease or is at risk of developing graft-versus-host disease. GVHD is a possible complication of any transplant using or containing stem cells from related or unrelated donors. There are two types of GVHD, acute and chronic. Acute GVHD appears within the first three months after transplantation. Signs of acute GVHD include a red rash on the hands and feet that may spread and become more severe, with peeling or blistering of the skin. Acute GVHD can also affect the stomach and intestines, in which case cramps, nausea and diarrhea can occur. Yellowing of the skin and eyes (jaundice) indicates that acute GVHD has affected the liver. Chronic GVHD is graded according to its severity: stage / grade 1 is mild; stage / grade 4 is severe. Chronic GVHD develops three months or later after transplantation. The symptoms of chronic GVHD are similar to those of acute GVHD, but in addition, chronic GVHD may also affect the mucous glands of the eyes, the salivary glands of the mouth, and the glands that lubricate the gastric mucosa and the intestines. Any immune cell population disclosed herein can be utilized. Examples of transplanted organs include solid organ transplants, such as kidneys, livers, skin, pancreas, lungs, and / or hearts, or cell transplants, such as islets, hepatocytes, myoblasts, bone marrow, or hematopoietic or other stem cells. The transplant can be a composite transplant, such as facial tissue. The immune cells can be administered before, at the same time as, or after the transplant. In some embodiments, the immune cells are administered before the transplant, such as at least 1 hour, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, or at least 1 month before the transplant. In a specific, non-limiting example, the administration of a therapeutically effective amount of immune cells is performed 3-5 days before the transplant.

[0233] In some embodiments, non-myeloablative lymphocyte depletion chemotherapy can be administered to the subject prior to immune cell therapy. Non-myeloablative lymphocyte depletion chemotherapy can be any suitable such therapy, which can be administered by any suitable route. Non-myeloablative lymphocyte depletion chemotherapy can include, for example, administration of cyclophosphamide and fludarabine, particularly if the cancer is a metastatic melanoma. An exemplary route for administering cyclophosphamide and fludarabine is intravenous. In addition, any suitable dose of cyclophosphamide and fludarabine can be administered. In a particular aspect, administration of about 60 mg / kg of cyclophosphamide continues for two days, followed by administration of about 25 mg / m 2 Fludarabine was continued for five days.

[0234] In certain embodiments, the growth factor that promotes MSC growth and activation is administered to the subject simultaneously with MSC and / or after MSC. Growth factor can be any suitable growth factor that promotes MSC growth and activation. Examples of suitable immune cell growth factors include interleukin (IL) -2, IL-7, IL-12, IL-15, IL-18 and IL-21, which can be used alone or in a variety of combinations, such as IL-2 and IL-7, IL-2 and IL-15, IL-7 and IL-15, IL-2, IL-7 and IL-15, IL-12 and IL-7, IL-12 and IL-15 or IL-12 and IL2.

[0235] Therapeutically effective amounts of the produced MSCs can be administered by a variety of routes, including parenteral administration, such as intravenous, intraperitoneal, intramuscular, intrasternal, intratumoral, intrathecal, intracerebroventricular, via a reservoir, intraarticular injection or infusion.

[0236] The therapeutically effective amount of MSCs produced for adoptive cell therapy is the amount that achieves the desired effect in the treated subject. For example, this can be the amount of immune cells that are necessary to suppress the progression of autoimmune or alloimmune diseases or cause the regression of autoimmune or alloimmune diseases or can alleviate the symptoms (such as pain and inflammation) caused by autoimmune diseases. It may be the amount necessary to alleviate the symptoms (such as pain, edema and fever) associated with inflammation. It can also be the amount necessary to reduce or prevent transplant organ rejection.

[0237] The resulting MSC population can be administered in a treatment regimen consistent with the disease, such as a single or several doses over one to several days to improve the disease state, or regular doses over an extended period of time to inhibit disease progression and prevent disease recurrence. The exact dose to be used in the formulation will also depend on the route of administration and the severity of the disease or condition, and should be determined based on the judgment of the practitioner and the circumstances of each patient. The therapeutically effective amount of MSCs will depend on the subject being treated, the severity and type of the disease, and the mode of administration. In some embodiments, a dose of at least 3.8×10 4 , at least 3.8×10 5 , at least 3.8×10 6 , at least 3.8×10 7 , at least 3.8×10 8 , at least 3.8×10 9 or at least 3.8×10 10 MSC / m 2 In certain embodiments, the dosage range for treating human subjects is about 3.8×10 9 About 3.8×10 10 MSC / m 2In other embodiments, the therapeutically effective amount of MSCs may be about 5×10 6 cells / kg body weight to about 7.5×10 8 cells / kg body weight, for example, about 2×10 7 cells to about 5×10 8 cells / kg body weight, or about 5×10 7 cells to about 2×10 8 The exact amount of MSCs is easily determined by a person skilled in the art based on the age, weight, sex and physiological condition of the subject. The effective dose can be inferred from a dose-response curve derived from an in vitro or animal model test system.

[0238] MSCs can be administered in combination with one or more other therapeutic agents for the treatment of immune-mediated disorders. Combination therapy may include, but is not limited to, one or more antimicrobial agents (e.g., antibiotics, antivirals, and antifungals), antineoplastic agents (e.g., fluorouracil, methotrexate, paclitaxel, fludarabine, etoposide, doxorubicin, or vincristine), immunodepleting agents (e.g., fludarabine, etoposide, doxorubicin, or vincristine), immunosuppressive agents (e.g., azathioprine or a glucocorticoid, such as dexamethasone or prednisone), anti-inflammatory agents (e.g., a glucocorticoid, such as hydrocortisone, dexamethasone, or prednisone, or a nonsteroidal anti-inflammatory agent such as acetylsalicylic acid, ibuprofen, or naproxensodium), cytokines (e.g., interleukin-10 or transforming growth factor-β), hormones (e.g., estrogen), or vaccines. In addition, immunosuppressants or tolerogenic agents may be administered, including but not limited to calcineurin inhibitors (e.g., cyclosporin and tacrolimus); mTOR inhibitors (e.g., rapamycin); mycophenolate mofetil, antibodies (e.g., recognizing CD3, CD4, CD40, CD154, CD45, IVIG, or B cells); chemotherapeutic agents (e.g., methotrexate, Treosulfan, Busulfan); irradiation; or chemokines, interleukins, or inhibitors thereof (e.g., BAFF, IL-2, anti-IL-2R, IL-4, JAK kinase inhibitors). Depending on the desired effect, such additional agents may be administered before, during, or after administration of the immune cells. Such administration of cells and agents may be by the same route or by different routes, and may be at the same site or at different sites.

[0239] A. Pharmaceutical Composition

[0240] Also provided herein are pharmaceutical compositions and formulations comprising MSCs produced by the methods encompassed herein and a pharmaceutically acceptable carrier.

[0241] The pharmaceutical compositions and formulations described herein can be prepared by mixing an active ingredient (e.g., an antibody or polypeptide) having a desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 22nd edition, 2012), in the form of a lyophilized formulation or an aqueous solution. Pharmaceutically acceptable carriers are generally non-toxic to recipients at the doses and concentrations employed, and include, but are not limited to: buffers, such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol, or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants, such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein also include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), such as human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 ( Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglucanases (e.g., chondroitinases).

[0242] B. Combination therapy

[0243] In certain embodiments, the compositions and methods of the present embodiment relate to MSC populations in combination with at least one additional therapy. Additional therapy can be radiotherapy, surgery (e.g., lumpectomy and mastectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy (except MSC cell therapy covered herein), bone marrow transplantation, nanotherapy, monoclonal antibody therapy or a combination of the foregoing. Additional therapy can be in the form of adjuvant therapy or neoadjuvant therapy.

[0244] In some embodiments, additional therapy is the administration of one or more small molecule enzyme inhibitors and / or one or more anti-metastatic agents. In some embodiments, additional therapy is the administration of side effect limiters (e.g., agents intended to reduce the occurrence and / or severity of the side effects of treatment, such as anti-nausea agents, etc.). In some embodiments, additional therapy is radiotherapy. In some embodiments, additional therapy is surgery. In some embodiments, additional therapy is a combination of radiotherapy and surgery. In some embodiments, additional therapy is gamma irradiation. In some embodiments, additional therapy is targeted PBK / AKT / mTOR pathway therapy, HSP90 inhibitors, tubulin inhibitors, apoptosis inhibitors and / or chemopreventive agents. Additional therapy can be one or more chemotherapeutic agents known in the art.

[0245] The MSC therapy of the present disclosure can be applied before, during, after or in various combinations relative to other cancer therapies (such as immune checkpoint therapy). The application interval can be from simultaneously to several minutes to several days to several weeks. In the embodiment in which the MSC therapy is provided to the patient separately from the other therapeutic agent, it is generally ensured that there is no significant time period between the time of each delivery, so that the two compounds will still be able to play a combined effect that is beneficial to the patient. In such a case, it is expected that antibody therapy and anticancer therapy can be provided to the patient within about 12 to 24 or 72 hours, more specifically within about 6-12 hours from each other. In some cases, it may be expected that the treatment time will be significantly extended, wherein a few days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) pass between each application.

[0246] Various combinations can be used. For the following example, immune cell therapy is "A", and anti-cancer therapy is "B":

[0247] A / B / AB / A / BB / B / AA / A / BA / B / BB / A / AA / B / B / BB / A / B / B

[0248] B / B / B / AB / B / A / BA / A / B / BA / B / A / BA / B / B / AB / B / A / A

[0249] B / A / B / AB / A / A / BA / A / A / BB / A / A / AA / B / A / AA / A / B / A

[0250] Administration of any compound or therapy of the present embodiments to a patient will follow general protocols for administration of such compounds, taking into account the toxicity, if any, of the agent. Thus, in some embodiments, there is a step of monitoring toxicity due to the combination therapy.

[0251] 1. Chemotherapy

[0252] According to an embodiment of the present invention, a variety of chemotherapeutic agents can be used. The term "chemotherapy" refers to the use of drugs to treat cancer. "Chemotherapeutic agent" is used to represent a compound or composition used in the treatment of cancer. These agents or drugs are classified according to their intracellular activity mode (e.g., whether they affect the cell cycle and at what stage the cell cycle is affected). Alternatively, agents can be characterized based on their ability to directly cross-link DNA, insert DNA, or induce chromosome and mitotic aberrations by affecting nucleic acid synthesis.

[0253] Examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclophosphamide; alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylamelamines, including altretamine, triethylenemelamine, and melamine. ), trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (particularly bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; callystatin; CC-1065 (including its adolesin derivative); elesin, carzelesin and bizelesin synthetic analogs); cryptophycin (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, chlornabucil, phazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard;Nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, particularly calicheamicin gamma II and calicheamicin omega II); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin; and the neocarcinogen chromophores and related chromoprotein enediyne antibiotics. Chromophores, aclacinomysin, actinomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, quercetin, lamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folate analogs such as leucovorin, pteropterin, and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiopurine, and thioguanine;Pyrimidine analogs such as cyclocytidine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; adrenal antistagnation drugs such as mitotane and trilostane; folic acid supplements such as folinic acid; aceglatone; aldophosphamide glycosides; androgens such as oxadiazine, dapoxetine, dapoxetine, and dapoxetine. glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptonium acetate; epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid acid; 2-ethylhydrazines; methylbenzylhydrazine; PSK polysaccharide complex; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triazinon; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, mucin A, baculosporin A, and anguidine); urethan; vindesine; dacarbazine; mannomustine; dibromomannitol; dibromodulanol; pipobroman;gacytosine; cytarabine ("Ara-C"); cyclophosphamide; taxanes such as paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunorubicin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; carboplatin, procarbazine, plicomycin, gemcitabine, navelbine, farnesyl protein transferase inhibitors, transplatinum and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing. ;

[0254] 2. Radiation therapy

[0255] Other factors that cause DNA damage and have been widely used include the directional delivery of commonly known gamma rays, X-rays and / or radioisotopes to tumor cells. Other forms of DNA damaging factors, such as microwaves, proton beam irradiation and UV irradiation, may also be considered. Most likely, all of these factors affect the extensive damage to DNA, DNA precursors, replication and repair of DNA, and assembly and maintenance of chromosomes. The dosage range of X-rays ranges from daily doses of 50 to 200 roentgens for a long time (3-4 weeks) to single doses of 2000 to 6000 roentgens. The dosage range of radioisotopes varies widely and depends on the half-life of the isotope, the intensity and type of the irradiation emitted, and the absorption of tumor cells.

[0256] 3. Immunotherapy

[0257] Those skilled in the art will appreciate that other immunotherapies may be combined or used in conjunction with the methods of the embodiments. In the context of cancer treatment, immunotherapy generally relies on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab is such an example. Immune effectors can be, for example, antibodies that are specific to certain markers on the surface of tumor cells. A single antibody can serve as an effector of therapy, or it can recruit other cells to actually affect cell killing. Antibodies can also be conjugated to drugs or toxins (chemotherapeutic agents, radionuclides, ricin A chain, cholera toxin, pertussis toxin, etc.) and used as targeting agents. Alternatively, effectors can be lymphocytes that carry surface molecules that interact directly or indirectly with tumor cell targets. Various effector cells include cytotoxic T cells and NK cells.

[0258] Antibody-drug conjugates (ADCs) contain a monoclonal antibody (MAb) covalently linked to a cytocidal drug and can be used in combination therapy. This approach combines the high specificity of a MAb for its antigenic target with a highly potent cytotoxic drug, resulting in an "armed" MAb that delivers the payload (drug) to tumor cells with abundant antigen levels. Targeted delivery of the drug also minimizes its exposure to normal tissues, thereby reducing toxicity and improving the therapeutic index. Exemplary ADC drugs include (brentuximab vedotin) and (trastuzumab emtansine or T-DM1).

[0259] In one aspect of immunotherapy, tumor cells must carry some markers that are easy to target, i.e., they are not present on most other cells. There are many tumor markers, and in the context of embodiments of the present invention, any of these tumor markers may be suitable for targeting. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, sialylated Lewis antigens, MucA, MucB, PLAP, laminin receptor, erbB and p155. An optional aspect of immunotherapy is to combine anticancer effects with immunostimulatory effects. There are also immunostimulatory molecules, including: cytokines, such as IL-2, IL-4, IL-12, GM-CSF, γ-IFN, chemokines, such as MIP-1, MCP-1, IL-8 and growth factors, such as FLT3 ligand.

[0260] Examples of immunotherapy include immune adjuvants, such as Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene and aromatic compounds; cytokine therapy, such as interferon α, β and γ, IL-1, GM-CSF and TNF; gene therapy, such as TNF, IL-1, IL-2 and p53; and monoclonal antibodies, such as anti-CD20, anti-ganglioside GM2 and anti-p185. It is contemplated that one or more anti-cancer therapies may be used together with the antibody therapies described herein.

[0261] In some embodiments, immunotherapy can be an immune checkpoint inhibitor. Immune checkpoints turn up signals (e.g., co-stimulatory molecules) or turn down signals. Inhibitory immune checkpoints that can be targeted by immune checkpoint blockade include adenosine A2A receptor (A2AR), B7-H3 (also known as CD276), B and T lymphocyte attenuator (BTLA), cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152), indoleamine 2,3-dioxygenase (IDO), killer cell immunoglobulin (KIR), lymphocyte activation gene 3 (LAG3), programmed death 1 (PD-1), T cell immunoglobulin domain and mucin domain 3 (TIM-3), and V-domain Ig inhibitor of T cell activation (VISTA). In particular, immune checkpoint inhibitors target the PD-1 axis and / or CTLA-4.

[0262] Immune checkpoint inhibitors can be drugs, such as small molecules, recombinant forms of ligands or receptors, or in particular antibodies, such as human antibodies. Known inhibitors of immune checkpoint proteins or their analogs can be used, in particular chimeric, humanized or human forms of antibodies can be used. As will be known to those skilled in the art, alternatives and / or equivalent names can be used for certain antibodies mentioned in the present disclosure. In the context of the present disclosure, such alternatives and / or equivalent names are interchangeable. For example, lambrolizumab is also known as alternative and equivalent names MK-3475 and pembrolizumab.

[0263] In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partner. In a specific aspect, the PD-1 ligand binding partner is PDL1 and / or PDL2. In another embodiment, a PDL1 binding antagonist is a molecule that inhibits the binding of PDL1 to its binding partner. In a specific aspect, the PDL1 binding partner is PD-1 and / or B7-1. In another embodiment, a PDL2 binding antagonist is a molecule that inhibits the binding of PDL2 to its binding partner. In a specific aspect, the PDL2 binding partner is PD-1. The antagonist can be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein or an oligopeptide.

[0264] In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the anti-PD-1 antibody is selected from nivolumab, pembrolizumab, and CT-011. In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 binding antagonist is AMP-224. Nivolumab (also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558 and ) is an anti-PD-1 antibody that can be used. Pembrolizumab (also known as MK-3475, Merck3475, lambrolizumab, and SCH-900475) are exemplary anti-PD-1 antibodies. CT-011 (also known as hBAT or hBAT-1) is also an anti-PD-1 antibody. AMP-224 (also known as B7-DCIg) is a PDL2-Fc fusion soluble receptor.

[0265] Another immune checkpoint that can be targeted in the methods provided herein is cytotoxic T lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The Genbank accession number of the complete cDNA sequence of human CTLA-4 is L15006. CTLA-4 is found on the surface of T cells and acts as a "close" switch when bound to CD80 or CD86 on the surface of antigen presenting cells. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of helper T cells and transmits inhibitory signals to T cells. CTLA4 is similar to T cell co-stimulatory protein CD28, and both molecules bind to CD80 and CD86 (also referred to as B7-1 and B7-2, respectively) on antigen presenting cells. CTLA4 transmits inhibitory signals to T cells, while CD28 transmits stimulatory signals. Intracellular CTLA4 is also present in regulatory T cells and may be important for their function. T cell activation by T cell receptors and CD28 leads to increased expression of CTLA-4 (inhibitory receptor for B7 molecules).

[0266] In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.

[0267] Anti-human-CTLA-4 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the methods of the invention can be produced using methods well known in the art. Alternatively, art-recognized anti-CTLA-4 antibodies can be used. Exemplary anti-CTLA-4 antibodies are ipilimumab (also known as 10D1, MDX-010, MDX-101 and ) or its antigen-binding fragments and variants. In other embodiments, the antibody comprises the heavy and light chain CDRs or VRs of ipilimumab. Thus, in one embodiment, the antibody comprises the CDR1, CDR2 and CDR3 domains of the VH region of ipilimumab, and the CDR1, CDR2 and CDR3 domains of the VL region of ipilimumab. In another embodiment, the antibody competes for binding to the same epitope on CTLA-4 as the above-mentioned antibodies and / or binds to the same epitope on CTLA-4 as the above-mentioned antibodies. In another embodiment, the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with ipilimumab).

[0268] 4. Surgery

[0269] Approximately 60% of cancer patients will undergo some type of surgery, including preventive, diagnostic or staging, curative, and palliative surgery. Curative surgery includes resection (in which all or part of the cancerous tissue is physically removed, excised, and / or destroyed) and may be used in conjunction with other therapies (e.g., treatment of the present embodiment, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapy). Tumor resection refers to the physical removal of at least a portion of a tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs surgery).

[0270] After removing part or all of the cancer cells, tissues or tumors, a cavity may be formed in the body. Treatment may be accomplished by perfusing, directly injecting or topically applying other anti-cancer therapies to the area. For example, this treatment may be repeated every 1, 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3, 4 and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. These treatments may also have different dosages.

[0271] 5. Other medicines

[0272] It is expected that other agents can be used in combination with certain aspects of the embodiments of the present invention to improve the efficacy of treatment. These additional agents include agents that affect the upregulation of cell surface receptors and GAP connections, cell growth inhibitors and differentiation agents, cell adhesion inhibitors, agents that increase the sensitivity of overproliferation cells to apoptosis inducing agents or other biological agents. Increasing intercellular signal transduction by increasing the number of GAP connections will increase the anti-overproliferation effect on neighboring overproliferation cell groups. In other embodiments, cell growth inhibitors or differentiation agents can be used in combination with certain aspects of the embodiments of the present invention to improve the anti-overproliferation efficacy of treatment. It is expected that cell adhesion inhibitors can improve the efficacy of the embodiments of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAK) inhibitors and lovastatin. It is further considered that other agents (such as antibody c225) that increase the sensitivity of overproliferation cells to apoptosis are used in combination with certain aspects of the embodiments of the present invention to improve the therapeutic efficacy.

[0273] VII. Preparation or Kit

[0274] Also provided herein are products or kits comprising immune cells. Products or kits comprising engineered MSCs and / or one or more reagents for producing them are provided. V can be from any source and can be produced by the methods encompassed herein, or the kit can include reagents for producing such engineered MSCs. In some embodiments, MSCs have been modified and can be provided in a kit so that they can be further modified, such as by gene editing and / or expressing one or more heterologous antigen receptors. In a specific embodiment, MSCs have been modified to express one or more heterologous antigen receptors and / or to be gene edited, and can be provided in a kit so that they can be further modified. In a specific embodiment, MSCs have been modified to be gene edited, and can be provided in a kit so that they can be further modified to express one or more heterologous antigen receptors.

[0275] In a specific embodiment, one or more reagents for producing MSCs are provided in the kit, such as reagents targeting specific genes, reagents comprising one or more heterologous antigen receptors (or one or more reagents producing one or more heterologous antigen receptors), cytokine transfection or transduction vectors or expression constructs or combinations thereof. In general embodiments, reagents may include nucleic acids including DNA or RNA, proteins, culture media, buffers, salts, cofactors, etc. In certain cases, the kit includes one or more CRISPR-related reagents, including for targeting specific desired genes.

[0276] The article or kit may further include a package insert containing instructions for using immune cells to treat or delay the progression of cancer in an individual or to enhance the immune function of an individual suffering from cancer. Any antigen-specific immune cell described herein may be included in the article or kit. Suitable containers include, for example, bottles, vials, bags, and syringes. The container can be formed of a variety of materials, such as glass, plastics (such as polyvinyl chloride or polyolefins) or metal alloys (such as stainless steel or Hastelloy). In some embodiments, the container holds the preparation, and the label on the container or associated with the container can indicate instructions for use. The article or kit may also include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In some embodiments, the article also includes one or more other agents (such as chemotherapeutic agents and anti-tumor agents). Suitable containers for one or more agents include, for example, bottles, vials, bags, and syringes. Example

[0277] The following examples are included to demonstrate preferred embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques that the inventors have found to work well in the practice of the present invention, and therefore can be considered to constitute preferred modes for its practice. However, in view of this disclosure, it will be appreciated by those skilled in the art that many changes can be made in the specific embodiments disclosed without departing from the spirit and scope of the present invention, and similar or similar results can still be obtained.

[0278] Example 1

[0279] Combined CAR transduction and CRISPR gene editing of MSC cells

[0280] Figure 1An example of a protocol for CAR transduction and CRISPR Cas9 editing of human mesenchymal stromal (MSC) cells from different sources is described. MSCs isolated from umbilical cord tissue, bone marrow, adipose tissue, or peripheral blood (as an example) are expanded to at least the second generation (P2) in αMEM medium (complete medium) supplemented with 5% human platelet lysate (hPLT) and 1% L-glutamine, and then transduced with a retrovirus carrying a CAR and / or gene of interest. The transduced MSCs can be expanded for 7 days or about 7 days, and then the transduction efficiency can be verified. Subsequently, gene editing can be performed using a ribonucleoprotein complex (RNP) by CRISPR-cas9 gene editing technology, such as in a 4D Nucleofector. Afterwards, MSCs can be cultured in complete medium for 7 days or about 7 days, and in some cases, the culture medium is replaced about 2 times a week. In a specific embodiment, the MSC monolayer is trypsinized, and the knockout (KO) efficiency can be evaluated. Transduced cells and KO cells can be expanded, for example, using a bioreactor system for 7 days or about 7 days. The resulting cells may or may not be cryopreserved prior to use.

[0281] Figures 2A-2D The transduction efficiency of MSCs is shown. Figure 2A In the figure, representative histograms show that bone marrow (BM) derived MSCs (left) and umbilical cord tissue (CT) derived MSCs (right) were transduced with a retroviral vector expressing one example of a CAR (CAR CD5). Compared to untransduced MSCs and isotypes, the transduction efficiency of BM MSCs (detected by expression of CAR antibodies on the cell surface, using flow cytometry) was 66.5% efficient and the efficiency of CT MSCs was 98.4%. Figure 2B Representative histograms are provided showing that BM MSCs (left panel) and CT MSCs (right panel) were transduced with a retroviral vector expressing CAR CD38, with an efficiency of 63.9% for BM MSCs and 87.9% for isotype-specific MSCs compared to untransduced MSCs and isotype-specific MSCs. Figure 2C Analysis of representative histograms is shown showing that CT MSCs were transduced with a retroviral vector expressing fucosyltransferase 6 (FT6) with an efficiency of 83.6% compared to untransduced MSCs and isotypes. In this example, flow cytometry was used to detect transduction by expression of sialyl-Lewis X (sLeX) and Lewis (LeX) residues (HECA) on the cell surface. Figure 2D Representative histograms are provided showing that CT MSCs at passage 5 were transduced with retroviral vectors co-expressing FT6 (left panel) and membrane-bound IL-21 (right panel), with 46.8% efficiency for FT6 and 67.9% efficiency for IL-21 compared to untransduced MSCs and isotype.

[0282] The efficiency of CRISPR Cas9 gene editing of immunosuppressive genes expressed in CT MSCs was Figures 3A-3D Described in. Figure 3A Shown is a flow cytometry analysis of the KO efficiency of CD47 gene editing in MSCs targeting exon 2 compared to a Cas9 control. The guide RNA for CD47 is provided as SEQ ID NO: 1 (CTACTGAAGTATACGTAAAG). Figure 3B Shown is a DNA electrophoresis gel demonstrating the KO efficiency of CRISPR Cas9 gene editing of the CD47 gene in MSCs using guides targeting exon 1 and targeting exon 2. Figure 3C Shown are flow cytometric analyses of the KO efficiency of the immunosuppressive genes PD-L1 (left panel) or PD-L2 (right panel) as single guides (blue) in CT MSCs compared to Cas9 control (red). Figure 3D Shown is flow cytometry analysis of the KO efficiency of simultaneous editing of the immunosuppressive genes PD-L1 and PD-L2 (blue) in CT MSCs compared to Cas9 alone (red) as a control.

[0283] Figures 4A-4C Transduction and function of CT-derived MSCs with CD40L were demonstrated. In particular, Figure 4A Representative histograms are provided showing that CT MSCs were transduced with a CD40L-expressing retroviral vector with an efficiency of 87.1% compared to non-transduced MSCs assessed by flow cytometry. Figure 4B The bar graph shown demonstrates the consistency of MSC transduction with CD40L in culture (where P5, P6, and P7 refer to passages 5, 6, and 7). Figure 4C The inhibitory effect of CD3 / CD28 beads-induced proliferation of purified T lymphocytes was demonstrated in the presence of non-transduced MSCs or MSCs transduced at different ratios relative to T cell proliferation observed in the absence of MSCs (positive control) as assessed by flow cytometry.

[0284] FIG5 provides proliferation and functional studies of MSCs engineered by CRISPR Cas9 gene editing of immunosuppressive genes. Figure 5ACumulative population doubling levels (cPD) of knockout (KO) MSCs are shown. MSCs from passage 4 (P4) (75,000 cells) were seeded in 24-well plates and expanded for 7 days using complete medium, with the medium replaced twice a week. After that, trypLE was used to release the MSC monolayer, the cells were washed with complete medium and spun at 300g for 10 minutes. The cells were then resuspended in 1 ml of complete medium and counted using an automatic counter using acridine orange / propidium iodide staining (AO / PI). The cPD after each passage was calculated by applying the following formula: 2PD = number of harvested cells / number of seeded cells; cPD = Σn2 (PD1+PD2+:::+PDn), where PD refers to population doubling. After co-culture with CD4+T cells, the immunosuppressive potential of MSC KO cells and Cas9 control cells was tested in vitro by measuring the cytokine (IFNγ, IL-2, TNFa) secretion of CD4+ cells.

[0285] In view of the present disclosure, all methods disclosed and claimed herein can be made and performed without undue experimentation. Although the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the art that changes can be applied to the methods and the steps or sequence of steps of the methods without departing from the concept, spirit and scope of the present invention. More specifically, it will be apparent that certain chemical and physiologically related reagents can be substituted for the reagents described herein while obtaining the same or similar results. All such similar substitutions and modifications apparent to those skilled in the art are considered to be within the spirit, scope and concept of the present invention as defined by the appended claims.

Claims

1. An in vitro method for producing engineered mesenchymal stem cells / mesenchymal stromal cells (MSCs), wherein The following steps are involved: Expanding MSCs to produce expanded MSCs, wherein the expanded MSCs are delivered to the MSCs within the first, second, third or fourth passages, an effective amount of Cas9 or CpF1 and one or more guide RNAs for each of two endogenous genes to disrupt the expression of the two endogenous genes in the MSCs, The two endogenous genes are PDL-1 and PDL-2.

2. The method of claim 1, wherein the delivering step is further defined as two electroporation steps.

3. The method of claim 2, wherein the first delivery step comprises delivering a guide RNA targeted to a gene, and the second delivery step comprises delivering a guide RNA targeted to a gene, the gene in the second delivery step being different from the gene in the first delivery step.

4. An in vitro method for producing engineered mesenchymal stem cells / mesenchymal stromal cells (MSCs), wherein The following steps are involved: (a) expanding MSCs to produce expanded MSCs, wherein the expanded MSCs are within the first, second, third or fourth passage, Either (b1) and (c1) or (b2) and (c2): (b1) transducing or transfecting the MSCs of (a) with a vector encoding one or more heterologous antigen receptors to produce modified MSCs; (c1) after the first period of time, delivering an effective amount of Cas9 or CpF1 and one or more guide RNAs to the modified MSCs to disrupt the expression of endogenous genes in the MSCs, thereby generating gene-edited modified MSCs; or (b2) delivering an effective amount of Cas9 or CpF1 and one or more guide RNAs to the MSCs of (a) to disrupt the expression of endogenous genes in the MSCs, thereby generating gene-edited MSCs; (c2) after the first period of time, transducing or transfecting the gene-edited MSCs with a vector encoding one or more heterologous antigen receptors to produce gene-edited modified MSCs; The endogenous genes are PDL-1 and PDL-2. 5 . The method according to claim 4 , wherein the gene-edited modified MSCs are produced by steps (b1) and (c1).

6. The method of claim 4, wherein the gene-edited modified MSCs are produced by steps (b2) and (c2).

7. The method of claim 4, wherein steps (c1) and (b2) are each further defined as two or more delivery steps.

8. The method of claim 7, wherein the first delivering step comprises delivering a guide RNA targeted to a gene, and the second delivering step comprises delivering a guide RNA targeted to a gene, the gene in the second delivering step being different from the gene in the first delivering step.

9. The method of claim 8, wherein the duration between the first delivering step and the second delivering step is 2-3 days.

10. The method of claim 4, wherein the first period of time is between 3 days and 8 days.

11. The method of claim 4, wherein the delivering step is performed by electroporation.

12. The method of claim 11, wherein electroporation uses 200,000 to 1 x 10 9 MSCs.

13. The method of claim 11, wherein 200,000 to 2,000,000 cells are used for electroporation.

14. The method of claim 11, wherein electroporation uses 1,000,000 to 1 x 10 9 MSCs.

15. The method according to any one of claims 2-3 and 11-14, wherein the concentration of the guide RNA in the electroporation step is 3, 4 or 5 μM.

16. The method of any one of claims 2-3 and 11-14, wherein the concentration of Cas9 nuclease in the electroporation step is 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9 or 5 μM.

17. The method according to any one of claims 1-14, wherein the MSCs are derived from umbilical cord tissue, bone marrow, peripheral blood, adipose tissue, dental pulp or a mixture thereof.

18. The method of any one of claims 4-14, wherein the heterologous antigen receptor is a chimeric antigen receptor or a T cell receptor.

19. The method of any one of claims 4-14, wherein the heterologous antigen receptor targets a cancer antigen.

20. The method of any one of claims 4-14, wherein the heterologous antigen receptor targets an antigen selected from the group consisting of CD19, EBNA, CD123, HER2, CA-125, TRAIL / DR4, CD20, CD70, carcinoembryonic antigen, alpha-fetoprotein, CD56, AKT, Her3, epithelial tumor antigen, CD319 (CS1), ROR1, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, CD5, CD23, CD30, HERV-K, IL-11Rα, kappa chain, lambda chain, CSPG4, CD33, CD47, CLL-1, U5snRNP200, CD200, BAFF-R, BCMA, CD99, p53, mutant p53, Ras, mutant ras, c-Myc, cytoplasmic serine / threonine kinase, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MART-1, melanoma-associated antigen, BAGE, DAM-6, -10, GAGE-1, -2, -8, GAGE-3, -4, -5, -6, -7B, NA88-A, MC1R, mda-7, gp75, Gp100, PSA, PSM, tyrosine Tyrosinase, tyrosinase-related protein, TRP-1, TRP-2, ART-4, CAMEL, CEA, Cyp-B, hTERT, hTRT, iCE, MUC1, MUC2, phosphoinositide 3-kinase (PI3K), TRK receptor, PRAME, P15, RU1, RU2, SART-1, SART-3, Wilms tumor antigen, AFP, -catenin / m, caspase-8 / m, CDK-4 / m, ELF2M, GnT-V, G250, HAGE, HSP70-2M, HST-2, KIAA0205, MUM-1, MUM-2, MUM-3, myosin / m , RAGE, SART-2, TRP-2 / INT2, 707-AP, Annexin II, CDC27 / m, TPI / mbcr-abl, BCR-ABL, interferon regulatory factor 4 (IRF4), ETV6 / AML, LDLR / FUT, Pml / RAR, tumor-associated calcium signal transducer 1 (TACSTD1), TACSTD2, receptor tyrosine kinase, VEGFR2, cytoplasmic tyrosine kinase, integrin-linked kinase (ILK), signal transducer and activator of transcription STAT3, STATS and STATE, hypoxia-inducible factor, nuclear factor-κB (NF-B), Notch receptor, NYESO1, c-Met, mammalian target of rapamycin (mTOR), WNT, extracellular signal-regulated kinase (ERK) and its regulatory subunits, PMSA, PR-3, MDM2, mesothelin, renal cell carcinoma-5T4, SM22-α, carbonic anhydrase I (CAI) and IX (CAIX) (also known as G250), STEAD, TEL / AML1, GD2, proteinase 3, sarcoma translocation breakpoint, EphA2, ML-IAP, EpCAM, ER G, NA17, PAX3, ALK, androgen receptor, cyclin B1, polysialic acid, MYCN, RhoC, GD3, fucosyl GM1, mesothelin, PSCA, sLe, PLAC1, GM3, BORIS, Tn, GLoboH, NY-BR-1, RGsS, SAGE, SART3, STn, PAX5, OY-TES1, sperm protein 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE 1, B7H3, legumin, TIE2, Page4, MAD-CT-1, FAP, MAD-CT-2, fos-related antigen 1, CBX2, CLDN6, SPANX, TPTE, ACTL8, ANKRD30A, CDKN2A, MAD2L1, CTAG1B, SUNC1 and LRRN1, and combinations thereof.

21. The method of any one of claims 4-14, wherein the heterologous antigen receptor is a chimeric antigen receptor targeting CD5, CD38 or TRAIL / DR4.

22. The method according to any one of claims 1-14, wherein the method further comprises transducing or transfecting MSCs with a vector encoding fucosyltransferase 6, IL-21, IL-22, FAS ligand, TNF-α and / or TRAIL.

23. The method of any one of claims 1-14, wherein the MSCs are transduced or transfected with one or more heterologous cytokines.

24. The method of any one of claims 1-14, wherein any of the cells are analyzed.

25. The method of claim 24, wherein the cells are analyzed by functional assays, cytotoxicity assays and / or in vivo activity.

26. The method of claim 24, wherein the cells are analyzed by flow cytometry, mass cytometry, RNA sequencing, or a combination thereof.

27. The method of any one of claims 1-14, wherein any of the cells are stored.

28. The method of any one of claims 1-14, wherein any of the cells are cryopreserved.

29. The method of any one of claims 4-14, wherein after step (c1) or (c2), the cells are expanded before and / or after analysis by one or more functional assays.

30. The method of any one of claims 4-14, wherein after step (c1) or (c2), the cells are expanded before and / or after storage.

31. The method of any one of claims 4-14, wherein any expansion step expands the cells in a medium comprising platelet lysate, L-glutamine and / or heparin.

32. A population of MSCs produced by the method of any one of claims 1-31.

33. A composition comprising the population of claim 32.

34. The composition of claim 33, wherein the population is contained in a pharmaceutically acceptable carrier.

35. Use of MSCs produced by the method of any one of claims 1-31 in the preparation of a medicament for treating a medical condition in an individual.

36. Use according to claim 35, wherein the medical condition is cancer.

37. The use according to claim 36, wherein the cancer comprises a hematological malignancy or a solid tumor.

38. The use according to claim 35, wherein the medical condition is an infectious disease and / or an immune-related disorder.

39. The use according to any one of claims 35-38, wherein the MSCs are administered to the individual once or multiple times.

40. The use of claim 39, wherein when the MSCs are administered to the individual multiple times, the duration between administrations is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours.

41. The use of claim 39, wherein when the MSCs are administered to the individual multiple times, the duration between administrations is 1, 2, 3, 4, 5, 6 or 7 days.

42. The use of claim 39, wherein when the MSCs are administered to the individual multiple times, the duration between administrations is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months.

43. The use according to any one of claims 35-42, wherein an effective amount of one or more additional therapies for the medical condition is administered to the individual.

44. The use according to claim 43, wherein the additional therapy is administered to the individual before, during and / or after the administration of the MSCs.

45. A kit comprising MSCs produced by the method of any one of claims 1-31, and one or more reagents for producing the MSCs.